



上海瑛泰醫療器械股份有限公司

Shanghai INT Medical Instruments Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

Stock Code : 1501

INNOVATION SERVES HEALTH,
HIGH-QUALITY ACHIEVES EXCELLENCE

* For identification purposes only

INTERIM REPORT 2025

CONTENTS

2	CORPORATE INFORMATION
4	INTERIM RESULTS HIGHLIGHTS
5	MANAGEMENT DISCUSSION AND ANALYSIS
15	SUPPLEMENTARY INFORMATION
33	INDEPENDENT AUDITOR'S REVIEW REPORT
34	CONSOLIDATED STATEMENT OF PROFIT OR LOSS
35	CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
36	CONSOLIDATED STATEMENT OF FINANCIAL POSITION
38	CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
39	CONDENSED CONSOLIDATED CASH FLOW STATEMENT
40	NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS
63	DEFINITIONS

CORPORATE INFORMATION

Executive Directors

Dr. Liang Dongke (梁棟科) (*Chairman*)

Mr. Lin Sen (林森)

Non-Executive Directors

Dr. Song Yuan (宋媛)

Mr. Wang Ruiqin (王瑞琴)

Ms. Chen Hongqin (陳紅琴)

Mr. Zhang Hong (張泓)

(appointed as non-executive Director on 23 May 2025)

Mr. Zhang Weixin (張維鑫)

(ceased as non-executive Director on 23 May 2025)

Independent Non-Executive Directors

Mr. Jian Xigao (蹇錫高)

Mr. Hui Hung Kwan (許鴻群)

Mr. Xu Congli (徐從禮)

Supervisors

Ms. Ma Huifang (馬慧芳) (*Chairperson*)

Ms. Chen Jie (陳潔)

Mr. Shen Xiaoru (沈曉如)

Audit Committee

Mr. Hui Hung Kwan (許鴻群) (*Chairman*)

Mr. Xu Congli (徐從禮)

Dr. Song Yuan (宋媛)

Remuneration Committee

Mr. Jian Xigao (蹇錫高) (*Chairman*)

Mr. Hui Hung Kwan (許鴻群)

Dr. Liang Dongke (梁棟科)

Nomination Committee

Mr. Jian Xigao (蹇錫高) (*Chairman*)

(appointed as Chairman on 23 May 2025)

Mr. Xu Congli (徐從禮)

Dr. Song Yuan (宋媛)

(appointed as member on 23 May 2025)

Dr. Liang Dongke (梁棟科)

(ceased as member on 23 May 2025)

Joint Company Secretaries

Dr. Song Yuan (宋媛)

Ms. Leung Shui Bing (梁瑞冰)

Authorized Representatives

Dr. Liang Dongke (梁棟科)

Ms. Leung Shui Bing (梁瑞冰)

Auditors

International auditor:

KPMG

(Public Interest Entity Auditor registered in accordance
with the Accounting and Financial Reporting Council
Ordinance)

8th Floor

Prince's Building

10 Chater Road

Central

Hong Kong

Domestic auditor:

KPMG Huazhen LLP

Floor 25, Tower II, Plaza 66

1266 Nanjing West Road

Shanghai

PRC

Legal Advisers

As to Hong Kong law:

O'Melveny & Myers

31st Floor, AIA Central

1 Connaught Road Central

Hong Kong

As to PRC law:

DeHeng Shanghai Law Office

Floor 23, Sinar Mas Plaza

No. 501 East Da Ming Road

Shanghai

PRC

Registered Office in the PRC

Block 2, No. 925 Jin Yuan Yi Road

Jiading District, Shanghai

PRC

CORPORATE INFORMATION

Headquarters and Principal Place of Business in the PRC

Block 2, No. 925 Jin Yuan Yi Road
Jiading District, Shanghai
PRC

Principal Place of Business in Hong Kong

31/F, Tower Two, Times Square
1 Matheson Street, Causeway Bay
Hong Kong

H Share Registrar

Computershare Hong Kong Investor Services Limited

Shops 1712–1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wanchai, Hong Kong

Principal Bankers

China Construction Bank Corporation

Shanghai Jiangqiao Branch

1/F, No. 138 Jiayi Road
Jiading District, Shanghai
PRC

Agricultural Bank of China Limited

Shanghai Jiading Branch

2/F, No. 355 Tacheng Road
Jiading District, Shanghai
PRC

Stock Code

1501

Company Website

www.int-medical.com

INTERIM RESULTS HIGHLIGHTS

FINANCIAL HIGHLIGHTS

	Six-month period ended 30 June		Change
	2025 RMB'000	2024 RMB'000	
Revenue	461,075	392,322	17.52%
Gross profit	270,661	246,768	9.68%
Profit for the period	102,436	99,178	3.29%
Earnings per share			
Basic (in RMB)	0.57	0.58	-1.72%
Diluted (in RMB)	0.57	0.58	-1.72%

- The Group's revenue in the Reporting Period was approximately RMB461.08 million, representing an increase of approximately 17.52% or approximately RMB68.76 million as compared to approximately RMB392.32 million for the six-month period ended 30 June 2024. The increase was mainly due to the growth in sales volume of interventional medical devices and the growth in sales volume of agent business. The Group's revenue generated from sales of interventional medical devices in the Reporting Period was approximately RMB392.37 million (six-month period ended 30 June 2024: RMB345.48 million), representing an increase of approximately 13.57% or approximately RMB46.89 million as compared to those of the six-month period ended 30 June 2024, and the revenue generated from sales of agent business in the Reporting Period was approximately RMB32.41 million (six-month period ended 30 June 2024: RMB14.82 million), representing an increase of approximately 118.69% or approximately RMB17.59 million as compared to those of the six-month period ended 30 June 2024.
- During the Reporting Period, the Group's gross profit margin decreased from 62.90% to 58.70%. The Group's gross profit was approximately RMB270.66 million, as compared to approximately RMB246.77 million for the six-month period ended 30 June 2024. The decrease in the Group's gross profit margin was mainly due to the increase of sales of agent business which had a lower gross profit margin than those of self-made products.
- The Group's profit for the Reporting Period was approximately RMB102.44 million, representing an increase of approximately 3.29% as compared to approximately RMB99.18 million for the six-month period ended 30 June 2024.
- The Group's basic earnings per share in the Reporting Period was RMB0.57, as compared to RMB0.58 for the six-month period ended 30 June 2024. The Group's diluted earnings per share in the Reporting Period was RMB0.57, as compared to RMB0.58 for the six-month period ended 30 June 2024.
- The Board resolved not to declare any interim dividend for the Reporting Period.

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS OVERVIEW

We are a leading Chinese cardiovascular interventional device manufacturer as well as one of the few medical device groups that cover the entire industry chain from design and development of mold and equipment, product injection, product assembly, product packaging to sterilisation in the PRC. Our major products are primarily used for vascular surgeries.

The China government introduced reform policies to support the healthy and orderly development of the medical industry. The Central Committee of the Communist Party of China and the State Council issued “Opinions on Deepening the Reform of the Medical Security System”, calling for the incorporation of drugs, diagnosis and treatment items, and medical consumables with high clinical value and good economic evaluation into the scope of medical instrument payment, continued reform of centralized volume and full implementation of volume-based procurement of medical consumables. In 2021, National Healthcare Security Administration issued the “Notice on Issuing the Three-year Action Plan for the Reform of DRG/DIP Payment Mode”, aiming to establish a national unified, top-down linkage and internal and external coordination of payment mechanism, and continue to expand the coverage area of DRG/DIP payment mode. In July 2024, National Healthcare Security Administration issued the “Notice on the 2.0 version of the grouping scheme based on Diagnosis Related Groups and Diagnosis-Intervention Packet payment, and the deepening of related work”, aiming to optimize the reform of medical insurance payment modes, refine the grouping standards and execution mechanisms based on Diagnosis Related Groups (DRG) and Diagnosis-Intervention Packet (DIP) payment, and promote the standardization and normalization of medical insurance payment through precise grouping, flexible exemption, and full process management. Therefore, the Company, with comprehensive medical device registration certificates, strong research and development capabilities and leading brand marketing system, will have a greater advantage in the normalized DRG/DIP competition in the future.

The Group’s revenue in the Reporting Period was approximately RMB461.08 million, representing an increase of approximately 17.52% or approximately RMB68.76 million as compared to approximately RMB392.32 million for the six-month period ended 30 June 2024, due to the growth in sales volume of interventional medical devices and the growth in sales volume of agent business. The Group’s revenue generated from sales of interventional medical devices in the Reporting Period was approximately RMB392.37 million, representing an increase of approximately 13.57% or approximately RMB46.89 million as compared to approximately RMB345.48 million for the six months ended 30 June 2024 and the revenue generated from sales of agent business in the Reporting Period was approximately RMB32.41 million (six-month period ended 30 June 2024: RMB14.82 million), representing an increase of approximately 118.69% or approximately RMB17.59 million as compared to those of the six-month period ended 30 June 2024.

Comprehensive medical device registration certificates

During the Reporting Period, the Group has obtained 3 NMPA registration certificates for Class III medical devices and 5 PMMPA registration certificates for Class II medical devices. As at 30 June 2025, we have an aggregate of 43 NMPA registration certificates for Class III medical devices, 68 PMMPA registration certificates for Class II medical devices, 27 CE certificates and 25 FDA approvals.

MANAGEMENT DISCUSSION AND ANALYSIS

Strong research and development capabilities

Our research and development team consists of professionals who possess doctorate degrees and master's degrees and numerous talents who have over 10 years of experience in research and development of production, with adequate capabilities in the development of innovation products and sustainable improvement of research and development. As at 30 June 2025, we had 657 registered patents, 281 patents under application and 28 registered software copyrights.

Extensive distribution and sales network

We have an extensive distribution network and have developed and maintained stable relationships with our distributors. As at 30 June 2025, our PRC distributors cover 23 (31 December 2024: 23) provinces, 4 (31 December 2024: 4) directly-administered municipalities and 5 (31 December 2024: 5) autonomous regions in the PRC, and covering 3,735 (31 December 2024: 3,049) domestic hospitals in the PRC. In addition, we had 313 (31 December 2024: 281) overseas customers covering over 91 (31 December 2024: 86) countries and regions.

ACTIVITIES REVIEW

Subsidiaries

As at 30 June 2025, the Group had 24 (31 December 2024: 19) wholly-owned or holding subsidiaries engaging in the design and development of intervention or implantation medical devices used in fields including cardiovascular, neurological, peripheral, ENT, urinary and the design and development of equipment and moulds used for production of medical devices.

Formation of Joint Venture

Reference is made to the announcement of the Company dated 28 November 2024. On 28 November 2024, the Company entered into the investment agreement (the **"First Investment Agreement"**) with Mr. Lin Sen, Dr. Song Yuan, and Mr. Wang Ruiqin in relation to the formation of Shanghai INT Asset Management Co., Ltd.* (上海瑛泰資產管理有限公司) (currently known as Shanghai INT Investment Management Co., Ltd.* (上海瑛泰投資管理有限公司)) (**"Shanghai INT Investment Management"**), a joint venture which will be primarily engaged in investment management. On the same day, the Company entered into the investment agreement (the **"Second Investment Agreement"**) with Dr. Song Yuan, in relation to the formation of Shanghai INT Life Co., Ltd.* (上海瑛泰昇活商貿有限公司) (**"Shanghai INT Life"**), a joint venture which would be primarily engaged in the sale of cosmetics, supplements, and disposable medical products. Mr. Lin Sen is an executive Director and a member of senior management of the Company, Dr. Song Yuan is a non-executive Director, and Mr. Wang Ruiqin is a non-executive Director. Therefore, each of Mr. Lin Sen, Dr. Song Yuan, and Mr. Wang Ruiqin is a connected person of the Company under the Listing Rules. Accordingly, each of the formation of the Shanghai INT Investment Management and Shanghai INT Life constitutes connected transaction of the Company under Chapter 14A of the Listing Rules. As one or more applicable percentage ratios in respect of the formation of Shanghai INT Investment Management and Shanghai INT Life (whether on standalone basis or when aggregated with each other) exceeded 0.1% but less than 5.0%, the formation of each of Shanghai INT Investment Management and Shanghai INT Life was only subject to the reporting and announcement requirements but was exempted from the circular and independent shareholders' approval requirements under Chapter 14A of the Listing Rules. Shanghai INT Life was established in the PRC on 29 November 2024 and Shanghai INT Investment Management was established in the PRC on 27 March 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

Establishment of Limited Partnership

Reference is made to the announcement of the Company dated 27 February 2025 in relation to the establishment of a limited partnership. The Company entered into a partnership agreement with Shanghai Science & Technology Investment Co., Ltd.* (上海科技創業投資股份有限公司) (as the co-general partner and the Fund Manager), Shanghai Chenyao Xinchun Enterprise Management Service Co., Ltd.* (上海辰耀新晨企業管理服務有限公司) (as the co-general partner), Shanghai Venture Investment Co., Ltd.* (上海創業投資有限公司) (as a limited partner), Shanghai Xingjia Phase II Private Investment Fund Partnership (Limited Partnership)* (上海興嘉二期私募投資基金合夥企業(有限合夥)) (as a limited partner), and Shanghai Jiangqiao Yihong Investment Development Co., Ltd.* (上海江橋億虹投資發展有限公司) (as a limited partner) in relation to the establishment of, and investment in, the Shanghai Chenyao Xinchun Private Investment Fund Partnership (Limited Partnership)* (上海辰耀新晨私募投資基金合夥企業(有限合夥)) (the “**Chenyao Xinchun Fund**”). The Company shall participate in the Chenyao Xinchun Fund as a limited partner and make a capital commitment of RMB100.0 million. As the highest applicable percentage ratio (as defined in Rule 14.07 of the Listing Rules) in respect of the partnership agreement exceeds 5% but is less than 25%, the entering into the partnership agreement by the Company constitutes discloseable transaction of the Company which is subject to the reporting and announcement requirements, but is exempt from the shareholders’ approval requirement under Chapter 14 of the Listing Rules. Chenyao Xinchun Fund was established in the PRC on 11 February 2025.

Re-election and Appointment of Directors and Supervisors

Reference is made to the announcements of the Company dated 18 March 2025 and 23 May 2025 and the circular of the Company dated 8 May 2025 in relation to, among others, the re-election and appointment of Directors and Supervisors.

At the Company’s annual general meeting held on 23 May 2025 (the “**AGM**”), Dr. Liang Dongke and Mr. Lin Sen were re-elected as executive Directors; Dr. Song Yuan, Mr. Wang Ruiqin and Ms. Chen Hongqin were re-elected as non-executive Directors; Mr. Zhang Hong was appointed as non-executive Director; Mr. Jian Xigao, Mr. Hui Hung Kwan and Mr. Xu Congli were re-elected as independent non-executive Directors, of the Fourth Session of the Board. For biographical details of the Directors of the Fourth Session of the Board and other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, please refer to the announcements of the Company dated 18 March 2025 and 23 May 2025 and the circular of the Company dated 8 May 2025.

At the employee representatives’ meeting of the Company held on 18 March 2025, Ms. Chen Jie was re-elected democratically as an employee representative Supervisor of the Fourth Session of the Supervisory Committee until the date of the annual general meeting to be convened in 2028. At the AGM, Ms. Ma Huifang and Mr. Shen Xiaoru was re-elected as a shareholder representative Supervisor of the Fourth Session of the Supervisory Committee. For biographical details of the Supervisors of the Fourth Session of the Supervisory Committee and other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, please refer to the announcements of the Company dated 18 March 2025 and 23 May 2025 and the circular of the Company dated 8 May 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

Acquisition of Controlling Stake in the Target Company

Reference is made to the announcements of the Company dated 18 December 2024 and 21 May 2025 in relation to acquisition of controlling stake in the Target Company (as defined below). The Company entered into a formal acquisition agreement (the “**Formal Acquisition Agreement**”) with Shanghai Chenyue Weixin Medical Technology Co., Ltd.* (上海辰躍維新醫療科技有限公司) (“**Chenyue Weixin**”), Hangzhou Weiqiang Medical Technology Co., Ltd.* (杭州唯強醫療科技有限公司) (the “**Target Company**” or “**Hangzhou Weiqiang**”), Endonom Medical Holding Corporation, Endonom Medical (Hong Kong) Co., Limited (the “**Hong Kong Company**”), Mr. Michael Yi Wei ZHAO (趙亦偉), Mr. Zhenjun Zi (訾振軍), Trio Management Company Limited and Xin Nuo Tong, in relation to the Company and Chenyue Weixin (as the purchasers) conditionally agreed to acquire from the Hong Kong Company (as the seller) an aggregate of 81.83% equity interest in the Target Company at a total consideration of approximately RMB512.84 million, of which the Company will acquire the controlling stake with 51.70% equity interest in the Target Company at a consideration of approximately RMB324.04 million, subject to completion or waiver of the conditions precedents (the “**Acquisition**”). Upon completion of the Acquisition, the Target Company would be owned as to approximately 51.70% by the Company. As the highest applicable percentage ratio in respect of the Acquisition exceeds 5% but is less than 25%, the Acquisition constitutes a discloseable transaction for the Company under Chapter 14 of the Listing Rules. Upon the completion of the Acquisition on 21 May 2025, Hangzhou Weiqiang has become a non-wholly owned subsidiary of the Company and the Company has the right to appoint three out of five directors on the board of Hangzhou Weiqiang.

The Company made further capital injection into the Target Company after it becomes a non-wholly owned subsidiary of the Company. As at the date of this interim report, the Target Company owned as to approximately 53.84% by the Company.

OUTLOOK FOR THE SECOND HALF OF 2025

The Group will continue to deeply develop various fields of medical devices, and orderly promote the Company’s strategic planning and business layout. Looking forward to the second half of 2025, we will (1) promote the synergistic development of the Group’s various businesses through strategic initiatives combining extensional mergers and acquisitions and endogenous growth to achieve high-quality sustainable development of the Group; (2) continue to expand the product pipeline, increase research and development investment, inject strong impetus into innovation and accelerate the development of core products and obtaining approvals for new products; (3) with the accumulation of brand awareness and the successive launch of new products, we will fully expand our market territory, increase product market share, strengthen the Company’s brand building, and further elevate its value; and (4) relying on the research and development center invested and constructed by the Group, deeply explore the potential of automation and large-scale production, and lay a solid foundation for efficient production.

MANAGEMENT DISCUSSION AND ANALYSIS

FINANCIAL REVIEW

Revenue

The Group's revenue in the Reporting Period was approximately RMB461.08 million, representing an increase of approximately 17.52% or approximately RMB68.76 million as compared to approximately RMB392.32 million for the six-month period ended 30 June 2024. The increase was mainly due to the growth in sales volume of interventional medical devices and the growth in sales volume of agent business.

With respect to revenue categorized by different products, the Group's revenue generated from sales of interventional medical devices in the Reporting Period was approximately RMB392.37 million (six-month period ended 30 June 2024: RMB345.48 million), representing an increase of 13.57% as compared to those of the six-month period ended 30 June 2024, and the revenue generated from sales of agent business in the Reporting Period was approximately RMB32.41 million (six-month period ended 30 June 2024: RMB14.82 million), representing an increase of 118.69% as compared to those of the six-month period ended 30 June 2024.

Cost of Sales

The Group's cost of sales in the Reporting Period was approximately RMB190.41 million, representing an increase of approximately 30.82% or approximately RMB44.86 million as compared to approximately RMB145.55 million for the six-month period ended 30 June 2024.

Gross Profit and Gross Profit Margin

During the Reporting Period, the Group's gross profit margin decreased from 62.90% for the six-month period ended 30 June 2024 to 58.70% for the six-month period ended 30 June 2025. The Group's gross profit was approximately RMB270.66 million, as compared to approximately RMB246.77 million for the six-month period ended 30 June 2024. The decrease in the Group's gross profit margin was mainly due to the increase of sales of agent business which had a lower gross profit margin than those of self-made products.

Other Income

During the Reporting Period, other income of the Group was approximately RMB30.47 million, representing an increase of approximately 27.28% or approximately RMB6.53 million as compared to approximately RMB23.94 million for the six-month period ended 30 June 2024. The increase was mainly due to the increase of government grants.

Finance Costs

During the Reporting Period, the finance costs of the Group was approximately RMB2.92 million as compared to approximately RMB1.03 million for the six-month period ended 30 June 2024. The finance costs were interests arising from bank loans and lease liabilities.

Distribution Costs

The distribution costs of the Group in the Reporting Period were approximately RMB41.53 million, increased by approximately 23.56% or approximately RMB7.92 million as compared to approximately RMB33.61 million for the six-month period ended 30 June 2024. It constituted 9.01% of the total revenue as compared to 8.57% for the six-month period ended 30 June 2024.

Administrative Expenses

The administrative expenses of the Group in the Reporting Period were approximately RMB64.92 million, increased by approximately 17.57% or approximately RMB9.70 million as compared to approximately RMB55.22 million for the six-month period ended 30 June 2024, due to depreciation, amortization, additional taxes and fees for Shandong INT Innovative Medical Instruments Industrial Park.

MANAGEMENT DISCUSSION AND ANALYSIS

Research and Development Expenses

The total research and development expenses of the Group during the Reporting Period was approximately RMB91.67 million (for the six-month period ended 30 June 2024: RMB85.93 million), of which, expensed research and development expenditure was approximately RMB70.24 million (for the six-month period ended 30 June 2024: RMB70.75 million), and capitalized research and development expenditure was approximately RMB21.44 million (for the six-month period ended 30 June 2024: RMB15.18 million).

Income Tax Expenses

The Group's income tax expenses in the Reporting Period was approximately RMB18.27 million, representing an increase of approximately 57.91% or approximately RMB6.70 million as compared to approximately RMB11.57 million for the six-month period ended 30 June 2024. The effective income tax rate was 15.14% for the Reporting Period as compared to 10.45% for the six-month period ended 30 June 2024. It was mainly due to the increase in the amount of the income tax (income tax rate 25%) of a relevant subsidiary.

Profit for the period

The Group's profit for the Reporting Period was approximately RMB102.44 million, representing an increase of approximately 3.29% as compared to approximately RMB99.18 million for the six-month period ended 30 June 2024.

LIQUIDITY AND FINANCIAL RESOURCES

The Group has maintained a sound financial position during the Reporting Period. As at 30 June 2025, the Group's cash and cash equivalents amounted to approximately RMB480.21 million (31 December 2024: RMB521.95 million). For the six-month period ended 30 June 2025, net cash flow from operating activities of the Group amounted to approximately RMB122.66 million (six-month period ended 30 June 2024: RMB104.82 million).

The Group recorded total current assets of approximately RMB869.34 million as at 30 June 2025 (31 December 2024: approximately RMB892.13 million) and total current liabilities of approximately RMB695.54 million as at 30 June 2025 (31 December 2024: approximately RMB434.46 million). The current ratio (calculated by dividing the current assets by the current liabilities) of the Group was approximately 1.25 as at 30 June 2025 (31 December 2024: approximately 2.05) due to the increase of bank loans.

BORROWINGS AND GEARING RATIO

The Group has approximately RMB538.94 million loan borrowed from bank in the PRC as at 30 June 2025. As such, the gearing ratio is 29.08% (31 December 2024: 13.64%)(calculated by dividing loans and borrowings and lease liabilities by total equity).

CAPITAL STRUCTURE

Total equity attributable to equity shareholders of the Company amounted to approximately RMB1,875.90 million as at 30 June 2025 as compared to approximately RMB1,774.23 million as at 31 December 2024.

INTERIM DIVIDEND

The Board resolved not to declare any interim dividend for the six-month period ended 30 June 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

USE OF PROCEEDS FROM THE GLOBAL OFFERING

Upon completion of the Global Offering, the Company raised net proceeds of approximately RMB797.62 million (after deducting the listing fees and other expenses). As at 30 June 2025, the Company has utilized approximately RMB786.46 million of the net proceeds. As disclosed in the section headed “Future Plans and Use of Proceeds” in the prospectus of the Company dated 28 October 2019 and the announcements of the Company dated 7 July 2020, 31 March 2021, 20 June 2022 and 3 March 2024, the details of intended application of net proceeds are set out as follows:

	Revised allocation of the net proceeds		After revision/ unutilized net proceeds as at 1 January 2025	Utilized net proceeds during the Reporting Period	Utilized net proceeds up to 30 June 2025	Unutilized net proceeds up to 30 June 2025	Expected timeline of full utilization of the unutilized net proceeds
	(RMB million)	(Approximate percentage)	(RMB million)	(RMB million)	(RMB million)	(RMB million)	
Set up a research and development center and an additional production facility in Jiading, Shanghai	328.38	41.17%	–	–	328.38	–	Not applicable
Purchase additional and replacement of existing production equipment and automate production lines	110.07	13.80%	–	–	110.07	–	Not applicable
Expand our distribution network and coverage, collaborate with local distributors and intensify our marketing efforts	13.00	1.63%	–	–	13.00	–	Not applicable
General corporate purposes and fund our working capital	79.84	10.01%	–	–	79.84	–	Not applicable
Zhuhai Derui New Factory Project	110.00	13.79%	–	–	110.00	–	Not applicable
Construction of the Shandong INT Innovative Medical Instruments Industrial Park	156.33	19.60%	20.21	9.05	145.17	11.16	December 2025
Total	797.62	100.00%	20.21	9.05	786.46	11.16	

As at the date of this interim report, the unutilized net proceeds has been deposited in bank accounts maintained by the Company.

As at 30 June 2025, the Company has unutilized approximately RMB11.16 million of the net proceeds in Construction of the Shandong INT Innovative Medical Instruments Industrial Park, mainly due to the final payment of the construction has not been paid and is expected to be paid by the end of 2025.

EMPLOYEE REMUNERATION AND RELATIONS

As at 30 June 2025, the Group had a total of 2,007 employees, comparing to 1,735 employees as at 31 December 2024. The total cost of employees for the Reporting Period amounted to approximately RMB167.82 million (six-month period ended 30 June 2024: approximately RMB147.92 million). The Group provides employees with competitive remuneration and benefits, and the Group’s remuneration policies are formulated according to the assessment of individual performance and are periodically reviewed. The Group has adopted three share schemes, including the Share Incentive Scheme, the 2023 Share Incentive Scheme and the H Share Award and Trust Scheme to recognize the contributions of certain employees and help in retaining them for the Group’s operation and further development. The Group also provides training programs to employees, including new hire training for new employees and continuing technical training primarily for our research and development team to enhance their skill and knowledge.

MANAGEMENT DISCUSSION AND ANALYSIS

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the Reporting Period, no H Shares repurchased by the trustee of the H Share Award and Trust Scheme (during the year ended 31 December 2024: 800,000 H Shares). No awards was granted under the H Share Award and Trust Scheme as at 30 June 2025.

As at 30 June 2025, there were no treasury shares held by the Company.

Save as disclosed above, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares) during the Reporting Period.

SIGNIFICANT INVESTMENTS AND FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

As at 30 June 2025 and 31 December 2024, the Group had below significant investments (all of which are minority stake investments).

	At 30 June 2025						At 31 December 2024					
	Percentage of interests %	Cost of Investment RMB'000	Fair value RMB'000	Size relative to the Group's total assets %	Accumulated gain RMB'000	Dividend received during the Reporting Period RMB'000	Percentage of interests %	Cost of investment RMB'000	Fair value RMB'000	Size relative to the Group's total assets %	Accumulated gain RMB'000	Dividend received during the year ended 31 December 2024 RMB'000
Recognised as "financial assets at fair value through profit or loss"												
Ningbo Huaige Ruixin Venture Investment Partnership (Limited Partnership)* (寧波懷格銳信創業投資合夥企業(有限合夥))(the "Ruixin Fund")	15.83	50,000	57,636	2.00	7,636	—	15.83	50,000	54,696	2.42	4,696	—
Shanghai Huaige Int Start-up Investment Limited Partnership (L.P.)* (上海懷格聚泰創業投資合夥企業(有限合夥))(the "Int Fund")	25.00	50,000	48,245	1.68	13,634	—	25.00	50,000	49,047	2.17	14,436	15,389
Chengdu Huaige Guosheng Venture Investment Partnership (Limited Partnership)* (成都懷格國生創業投資合夥企業(有限合夥))(the "Chengdu Huaige Fund")	12.14	25,000	30,016	1.04	5,016	—	12.14	25,000	29,790	1.32	47,90	—
Hainan Renze Zhenchi Venture Capital Fund Partnership Enterprise (Limited Partnership)* (海南仁澤真奇創業投資基金合夥企業(有限合夥))(the "Hainan Renze Fund")	27.62	25,000	25,174	0.87	174	—	27.62	17,500	18,082	0.80	582	—
Shanghai Chenyao Xinchun Private Investment Fund Partnership (Limited Partnership)* (上海辰耀新晨私募基金合夥企業(有限合夥))(the "Chenyao Xinchun Fund")	32.26	100,000	99,511	3.46	(489)	—	—	—	—	—	—	—
		250,000	260,582	9.06	25,971	—		142,500	151,615	6.71	24,504	15,389

MANAGEMENT DISCUSSION AND ANALYSIS

The primary objective of the Ruixin Fund is investments in equity interest of entities in the medical devices, pharmaceutical, biologics, medical services and contract research organisation services industries mainly in the PRC and investments in other equity funds with focus of investing in the medical device and biomedical fields.

The primary objective of the Int Fund is venture investment in, among others, equity interests, convertible loans and/or financial assets in relation to start-ups or early-stage businesses in the medical devices industry mainly in the PRC. The investment priorities of the Int Fund include start-ups or early-stage businesses principally engaged in the research and development of cardiovascular interventional devices, neuro interventional procedural medical devices and other interventional medical devices.

The primary objective of the Chengdu Huaige Fund is venture investments in equity interests of early-stage or growth stage businesses in the healthcare and biotechnology sectors. The investment in the Chengdu Huaige Fund provides the Company with an opportunity to facilitate its strategic development in the healthcare and biotechnology and other related industries, enhance its competitiveness, and strengthen its market position.

The primary objective of the Hainan Renze Fund is investments in equity interest of entities in the medical and health field, including biotechnology, innovative drugs, medical services and medical devices, and the main investment stage is the Pre-IPO stage.

The primary objective of Chenyao Xinchun Fund is achieving investment returns through equity investments in medical devices companies.

Save as disclosed above, the Group has no other significant investment in the Reporting Period.

MATERIAL ACQUISITIONS AND DISPOSAL OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

In May 2025, the Company entered into Formal Acquisition Agreement with Endonom Medical (Hong Kong) Co., Limited (the “**Seller**”), which is the 100% shareholder of Hangzhou Weiqiang, pursuant to which the Company agreed to acquire 51.70% equity interests in Hangzhou Weiqiang from the Seller at a consideration of RMB324 million.

The transaction was completed on 21 May 2025, and as a result the Company held an aggregate of 51.70% equity interest in Hangzhou Weiqiang and has the right to appoint three out of five directors on the board of Hangzhou Weiqiang. The Company has determined that it acquired control over Hangzhou Weiqiang from that date. In arriving at this determination, the Company has considered, among other factors, its voting rights including its veto rights over certain decisions of Hangzhou Weiqiang and its board appointment rights, and the operational reliance of Hangzhou Weiqiang on the Group and its key management personnel. Detailed information is disclosed in the Company’s announcement dated 21 May 2025.

The Company made further capital injection into Hangzhou Weiqiang after it becomes a non-wholly owned subsidiary of the Company. As at the date of this interim report, Hangzhou Weiqiang owned as to approximately 53.84% equity interest by the Company.

Save as disclosed above, the Group has no material acquisitions or disposal of subsidiaries, associates and joint ventures during the Reporting Period.

MANAGEMENT DISCUSSION AND ANALYSIS

CONTINGENT LIABILITIES

As at 30 June 2025 and 31 December 2024, the Group did not have any material contingent liabilities.

FINANCIAL INSTRUMENTS

As at 30 June 2025, the Group did not enter into foreign forward contracts.

As at 30 June 2025, the Group did not have any other outstanding hedge contracts or financial derivative instruments (31 December 2024: nil).

CAPITAL EXPENDITURE

The capital expenditure of the Group for property, plant and equipment (the “PPE”), construction in progress, intangible assets, prepaid lease payments and deposits for PPE amounted to approximately RMB53.84 million for the Reporting Period.

FOREIGN EXCHANGE RISK

During the Reporting Period, the Group’s operations were primarily based in the PRC. The Group’s assets, liabilities and transactions in the PRC are denominated in RMB, while overseas assets and transactions are mainly denominated in US Dollars. There were currency fluctuations among US Dollars, Euro, RMB and Hong Kong Dollars during the Reporting Period, the Group’s operational results and financial condition may be affected by changes in the exchange rates. As the Group reasonably arranges the currency structure, which effectively reduces foreign exchange risk, the Directors believe that there is no significant foreign exchange risk to the Group at the current stage. Therefore, the Group had not implemented any formal hedging or other alternative policies to deal with such exposure during the Reporting Period. The Group will continuously monitor its foreign exchange exposure and will consider hedging of foreign currency risk should the need arise.

CHARGE ON GROUP ASSETS

As at 30 June 2025, the Group’s bank mortgage loans of RMB206.8 million were obtained through equity pledges of Company’s equity interest in Hangzhou Weiqiang (31 December 2024: none).

CAPITAL COMMITMENT

The Group’s outstanding capital commitments authorized but not contracted for at 30 June 2025 not provided for in the financial statements amounted to approximately RMB13.06 million (31 December 2024: RMB202.15 million). The Group’s outstanding capital commitment contracted for at 30 June 2025 not provided for in the financial statements amounted to approximately RMB57.49 million (31 December 2024: RMB89.05 million).

SUPPLEMENTARY INFORMATION

CORPORATE GOVERNANCE PRACTICES

The Board is committed to achieve good corporate governance standards to protect the Shareholders' interest and enhance the Company's transparency and accountability. The Company's corporate governance practices are based on the CG Code contained in Appendix C1 of the Listing Rules. During the Reporting Period, the Company has complied with all the code provisions set forth in the CG Code, except for code provision C.2.1 of Part 2 of the CG Code that requires the roles of chairman and chief executive should be separate and should not be performed by the same individual.

Dr. Liang Dongke is our chairman of the Board and the general manager (same as a chief executive) of the Company. Dr. Liang has extensive experience in the medical devices industry and have served in the Company since its establishment. He is in charge of overall management, business, strategic development and scientific research and development of the Group.

The Board considers that vesting the roles of chairman and general manager in the same person is beneficial to the management of the Group. The balance of power and authority is ensured by the Board, the Supervisors and the senior management of the Company, which comprises experienced and visionary individuals. The Board currently comprises two executive Directors (including Dr. Liang), four non-executive Directors and three independent non-executive Directors, and therefore has a strong independence element in its composition. The Board shall review the structure from time to time to ensure that the structure facilitates the execution of the Group's business strategies and maximizes effectiveness of its operation.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as set out in Appendix C3 to the Listing Rules as its code of conduct for Directors' and Supervisors' securities transactions. Having made specific enquiry with the Directors and the Supervisors, all of the Directors and the Supervisors confirmed that they have complied with the required standards set out in the Model Code during the Reporting Period. Employees who are, or likely to be, in possession of unpublished inside information in relation to the Company or the Shares are prohibited from dealing in the Shares during the black-out period.

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

The Company does not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

SUPPLEMENTARY INFORMATION

CHANGES IN INFORMATION OF THE DIRECTORS, AND SUPERVISORS AND CHIEF EXECUTIVE OF THE COMPANY

Save as disclosed in the 2024 annual report of the Company and the section headed “Activities Review — Re-election and Appointment of Directors and Supervisors” under Management Discussion and Analysis in this interim report, Mr. Zhang Weixin being a Director of the Third Session of the Board, retired upon expiration of the term of office of the Third Session of the Board (i.e. 23 May 2025, the date of the AGM).

Dr. Liang Dongke, an executive Director, ceased as a chairman and a member of the Nomination Committee on 23 May 2025. Dr. Song Yuan, a non-executive Director, was appointed as a member of the Nomination Committee on 23 May 2025. Mr. Xu Congli, an independent non-executive Director, was appointed as a chairman of the Nomination Committee on 23 May 2025.

Save as disclosed above, there was no change of the information of Directors, Supervisors and chief executive of the Company during the Reporting Period which is required to be disclosed pursuant to Rules 13.51B(1) and 13.51B(2) of the Listing Rules.

REVIEW OF FINANCIAL INFORMATION

Audit Committee

The Company has established the Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the CG Code as set out in Appendix C1 to the Listing Rules. The Audit Committee comprises three members, namely, Mr. Hui Hung Kwan, Mr. Xu Congli and Dr. Song Yuan. Mr. Hui and Mr. Xu are independent non-executive Directors and Dr. Song is a non-executive Director. Mr. Hui is the chairman of the Audit Committee, who possesses suitable professional qualifications. The Audit Committee has reviewed the Company’s unaudited interim results for the Reporting Period and confirms that the applicable accounting principles, standards and requirements have been complied with, and that adequate disclosures have been made. The Audit Committee has also discussed the risk management, internal control and financial reporting matters.

Independent Review of Auditor

KPMG, the Company’s auditor, has reviewed the Company’s unaudited interim financial report for the Reporting Period in accordance with Hong Kong Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Hong Kong Institute of Certified Public Accountants, whose unmodified review report is included in the interim report to be sent to the Shareholders.

SUPPLEMENTARY INFORMATION

INTERESTS AND SHORT POSITIONS OF THE DIRECTORS, SUPERVISORS AND CHIEF EXECUTIVES OF THE COMPANY IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As of 30 June 2025, the interests and short positions of the Directors, the Supervisors and the chief executives of the Company in the Shares, underlying Shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he/she is keen to taken or deemed to have under such provisions of the SFO), or as recorded in the register maintained by the Company under Section 352 of the SFO, or as notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

Name	Type of Shares	Nature of Interest	Number of Shares held/ interested ⁽¹⁾	Approximate percentage in Domestic Shares ⁽²⁾	Percentage in total number of Shares ⁽²⁾
Dr. Liang Dongke (梁棟科) ⁽³⁾	Domestic Shares	Beneficial owner	12,042,854 (L)	16.78%	6.84%
	Domestic Shares	Interest of controlled corporation	9,900,000 (L)	13.79%	5.63%
Dr. Song Yuan (宋媛) ⁽³⁾	Domestic Shares	Interest of spouse	21,942,854 (L)	30.57%	12.47%
Mr. Lin Sen (林森)	Domestic Shares	Beneficial owner	7,142,858 (L)	9.95%	4.06%
Mr. Wang Ruiqin (王瑞琴)	Domestic Shares	Beneficial owner	7,142,858 (L)	9.95%	4.06%

Notes:

(1) The letter "L" stands for long position.

(2) The calculation is based on percentage of shareholding in a total of 176,000,000 issued Shares, which consist of 71,786,608 Domestic Shares and 104,213,392 H Shares as at 30 June 2025.

(3) Dr. Song Yuan is the spouse of Dr. Liang Dongke. Under section 316(1)(a) of the SFO, Dr. Song Yuan is deemed to be interested in the equity interests held by Dr. Liang Dongke.

Save as disclosed above, as of 30 June 2025, to the best knowledge of the Board, none of the Directors, the Supervisors or chief executives of the Company had any interests or short positions in the Shares, underlying Shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be (i) notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which the Directors, the Supervisors and chief executives of the Company were taken or deemed to have under such provisions of the SFO); (ii) recorded in the register kept by the Company pursuant to Section 352 of the SFO; or (iii) notified to the Company and the Stock Exchange pursuant to the Model Code.

SUPPLEMENTARY INFORMATION

INTERESTS OF SUBSTANTIAL SHAREHOLDERS IN THE SHARES AND UNDERLYING SHARES

As of 30 June 2025, according to the register kept by the Company pursuant to Section 336 of the SFO and so far is known to, or can be ascertained after reasonable enquiry by the Directors, the following person/entity had an interests or short position in the Shares and underlying Shares which would fall to be disclosed to the Company and the Stock Exchange pursuant to Divisions 2 and 3 of Part XV of the SFO, or be directly and indirectly interested in 5% or more of the nominal value of any class of share capital carrying rights to vote on all circumstances at general meetings of the Company (the interests in Shares and/or short positions, if any, disclosed herein are in addition to those disclosed in respect of the Directors, Supervisors and chief executives of the Company):

Interests in the Shares of the Company

Name	Type of Shares	Nature of Interest	Number of Shares held/ interested ⁽¹⁾	Approximate percentage in the respective type of share capital ⁽¹¹⁾	Percentage in total number of Shares ⁽¹¹⁾
Ningbo Huaige Taiyi Equity Investment Partnership (Limited Partnership) (寧波懷格泰益股權投資合夥企業(有限合夥)) ("Ningbo Huaige Taiyi") ⁽²⁾	Domestic Shares	Beneficial owner	9,843,750 (L)	13.71%	5.59%
Ningbo Huaige Gongxin Equity Investment Partnership (Limited Partnership) (寧波懷格共信股權投資合夥企業(有限合夥)) ("Ningbo Huaige Gongxin") ⁽²⁾	Domestic Shares	Interest of controlled corporation	9,843,750 (L)	13.71%	5.59%
Ningbo Huaige Health Investment Management Partnership (Limited Partnership) (寧波懷格健康投資管理合夥企業(有限合夥)) ("Ningbo Huaige Health") ⁽²⁾	Domestic Shares	Interest of controlled corporation	9,843,750 (L)	13.71%	5.59%

SUPPLEMENTARY INFORMATION

Name	Type of Shares	Nature of Interest	Number of Shares held/ interested ⁽¹⁾	Approximate percentage in the respective type of share capital ⁽¹¹⁾	Percentage in total number of Shares ⁽¹¹⁾
Mr. Wang Kai (王鐸) ⁽²⁾	Domestic Shares	Beneficial owner	5,571,428 (L)	7.76%	3.17%
	Domestic Shares	Interests of controlled corporation	9,843,750 (L)	13.71%	5.59%
Ms. Zhao Wei (趙威) ⁽²⁾	Domestic Shares	Interest of spouse	15,415,178 (L)	21.47%	8.76%
Ms. Chen Saiying (陳賽英) ⁽³⁾	Domestic Shares	Interest of spouse	7,142,858 (L)	9.95%	4.06%
Ms. Han Chunyan (韓春燕) ⁽⁴⁾	Domestic Shares	Interest of spouse	7,142,858 (L)	9.95%	4.06%
Mr. Chen Xing (陳星) ⁽⁵⁾	Domestic Shares	Beneficial owner	7,071,430 (L)	9.85%	4.02%
Ms. Han Xue (韓雪) ⁽⁵⁾	Domestic Shares	Interest of spouse	7,071,430 (L)	9.85%	4.02%
Mr. Huang Chubin (黃楚彬) ⁽⁶⁾	Domestic Shares	Beneficial owner	7,071,430 (L)	9.85%	4.02%
Ms. Li Xiuqun (李秀群) ⁽⁶⁾	Domestic Shares	Interest of spouse	7,071,430 (L)	9.85%	4.02%
Ningbo Tongchuang Suwei Investment Partnership (Limited Partnership) (寧波同創速維投資合夥企業(有限合夥)) ("Ningbo Tongchuang Suwei") ⁽⁷⁾	Domestic Shares	Beneficial owner	6,000,000 (L)	8.36%	3.41%
Mr. Chai Yanpeng (柴燕鵬) ⁽⁷⁾	Domestic Shares	Interest of controlled corporation	6,000,000 (L)	8.36%	3.41%
Shanghai Kindly Enterprise Development Group Co., Ltd. (上海康德萊企業發展集團股份有限公司) ("KDL") ⁽⁸⁾	H Shares	Beneficial owner	42,857,142 (L)	41.12%	24.35%

SUPPLEMENTARY INFORMATION

Name	Type of Shares	Nature of Interest	Number of Shares held/interested ⁽¹⁾	Approximate percentage in the respective type of share capital ⁽¹¹⁾	Percentage in total number of Shares ⁽¹¹⁾
Shanghai Kindly Holding Group Co., Ltd. (上海康德萊控股集團有限公司) (“KDL Holding”) ⁽⁸⁾	H Shares	Interest of controlled corporation	42,857,142 (L)	41.12%	24.35%
Kindly Holding Co., Ltd. (康德萊控股有限公司) ⁽⁸⁾	H Shares	Interest of controlled corporation	42,857,142 (L)	41.12%	24.35%
Shanghai Gongye Investment Co., Ltd. (上海共業投資有限公司) (“Gongye”) ⁽⁸⁾	H Shares	Interest of controlled corporation	42,857,142 (L)	41.12%	24.35%
Mr. Zhang Xianmiao (張憲淼) ⁽⁸⁾	H Shares	Interest of controlled corporation; interest jointly held with another person	42,857,142 (L)	41.12%	24.35%
Ms. Zheng Aiping (鄭愛平) ⁽⁸⁾	H Shares	Interest of controlled corporation; interest jointly held with another person	42,857,142 (L)	41.12%	24.35%
Mr. Zhang Wei (張偉) ⁽⁸⁾	H Shares	Interest of controlled corporation; interest jointly held with another person	42,857,142 (L)	41.12%	24.35%
Ningbo Huaige Taiyi ⁽²⁾	H Shares	Beneficial owner	12,494,250 (L)	11.99%	7.10%
Ningbo Huaige Gongxin ⁽²⁾	H Shares	Interest of controlled corporation	12,494,250 (L)	11.99%	7.10%
Ningbo Huaige Health ⁽²⁾	H Shares	Interest of controlled corporation	12,494,250 (L)	11.99%	7.10%

SUPPLEMENTARY INFORMATION

Name	Type of Shares	Nature of Interest	Number of Shares held/ interested ⁽¹⁾	Approximate percentage in the respective type of share capital ⁽¹¹⁾	Percentage in total number of Shares ⁽¹¹⁾
Mr. Wang Kai (王鐸) ⁽²⁾	H Shares	Interest of controlled corporation	12,494,250 (L)	11.99%	7.10%
Ms. Zhao Wei (趙威) ⁽²⁾	H Shares	Interest of spouse	12,494,250 (L)	11.99%	7.10%
Central Huijin Investment Ltd. ⁽⁹⁾	H Shares	Interest of controlled corporation	17,719,200 (L)	17.00%	10.07%
China Orient Asset Management (International) Holding Limited ⁽⁹⁾	H Shares	Interest of controlled corporation	17,719,200 (L)	17.00%	10.07%
China Orient International Fund Management Limited ⁽⁹⁾	H Shares	Interest of controlled corporation	17,719,200 (L)	17.00%	10.07%
China Orient Multi-Strategy Fund ⁽⁹⁾	H Shares	Interest of controlled corporation	13,153,400 (L)	12.62%	7.47%
China Orient Multi-Strategy Master Fund ⁽⁹⁾	H Shares	Beneficial owner	13,153,400 (L)	12.62%	7.47%
OrbiMed Capital LLC ⁽¹⁰⁾	H Shares	Investment manager	9,000,000 (L)	8.64%	5.11%
Worldwide Healthcare Trust PLC ⁽¹⁰⁾	H Shares	Beneficial owner	7,200,000 (L)	6.91%	4.09%
Mr. Ke Wei (柯偉)	H Shares	Beneficial owner	6,070,000 (L)	5.82%	3.45%

SUPPLEMENTARY INFORMATION

Notes:

- (1) The letters “L” stands for long position.
- (2) To the best of the Directors’ knowledge, Ningbo Huaige Taiyi is a limited partnership established in the PRC and is owned as to 53.13% by Ningbo Huaige Gongxin as limited partner. Ningbo Huaige Health is the general partner of Ningbo Huaige Taiyi and Ningbo Huaige Gongxin. Mr. Wang Kai has 82.5% interest in Ningbo Huaige Health as the general partner. Ms. Zhao Wei is the spouse of Mr. Wang Kai. As such, under the SFO, each of Ningbo Huaige Gongxin, Ningbo Huaige Health, Mr. Wang Kai and Ms. Zhao Wei is deemed to be interested in the equity interests held by Ningbo Huaige Taiyi.
- (3) Ms. Chen Saiying is the spouse of Mr. Lin Sen. Under section 316(1)(a) of the SFO, Ms. Chen Saiying is deemed to be interested in the equity interests held by Mr. Lin Sen.
- (4) Ms. Han Chunyan is the spouse of Mr. Wang Ruiqin. Under section 316(1)(a) of the SFO, Ms. Han Chunyan is deemed to be interested in the equity interests held by Mr. Wang Ruiqin.
- (5) Ms. Han Xue is the spouse of Mr. Chen Xing. Under section 316(1)(a) of the SFO, Ms. Han Xue is deemed to be interested in the equity interests held by Mr. Chen Xing.
- (6) Ms. Li Xiuqun is the spouse of Mr. Huang Chubin. Under section 316(1)(a) of the SFO, Ms. Li Xiuqun is deemed to be interested in the equity interests held by Mr. Huang Chubin.
- (7) To the best of the Directors’ knowledge, Ningbo Tongchuang Suwei is a limited partnership established in the PRC. Mr. Chai Yanpeng is the general partner of Ningbo Tongchuang Suwei. As such, under the SFO, Mr. Chai Yanpeng is deemed to be interested in the equity interests held by Ningbo Tongchuang Suwei.
- (8) To the best of the Directors’ knowledge, KDL Holding controls KDL as it owns more than one-third of the voting power at general meetings of KDL. KDL Holding is in turn controlled by each of Gongye and Kindly Holding Co., Ltd. as each of Gongye and Kindly Holding Co., Ltd. owns more than one-third of the voting power at general meetings of KDL Holding. Gongye is held as to 56.43% and Kindly Holding Co., Ltd. is wholly-owned by the Zhang Family (namely, Mr. Zhang Xianmiao (張憲淼), Ms. Zheng Aiping (鄭愛平) and Mr. Zhang Wei (張偉)) as concert parties. As such, under the SFO, each of KDL Holding, Gongye, Kindly Holding Co., Ltd., Mr. Zhang Xianmiao, Ms. Zheng Aiping and Mr. Zhang Wei is deemed to be interested in the equity interests held by KDL.
- (9) To the best of the Directors’ knowledge, 13,153,400 H Shares held by China Orient Multi-Strategy Master Fund is controlled as to 100% by China Orient Multi-Strategy Fund, which is in turn controlled as to 100% by China Orient International Fund Management Limited, 100% of the voting power of which is controlled by China Orient Asset Management (International) Holding Limited. 4,565,800 H Shares held by China Orient Enhanced Income Fund is controlled as to 100% by China Orient International Fund Management Limited, 100% of the voting power of which is controlled by China Orient Asset Management (International) Holding Limited. China Orient Asset Management (International) Holding Limited is controlled as to 50% by Dong Yin Development (Holdings) Limited and 50% by Wise Leader Assets Ltd, which is in turn controlled as to 100% by Dong Yin Development (Holdings) Limited. Dong Yin Development (Holdings) Limited is controlled as to 100% by China Orient Asset Management Co. Ltd, which is in turn controlled as to 71.55% by Central Huijin Investment Ltd.. As such, under the SFO, each of Central Huijin Investment Ltd., China Orient International Fund Management Limited and China Orient Asset Management (International) Holding Limited is deemed to be interested in the equity interests held by China Orient Multi-Strategy Master Fund and China Orient Enhanced Income Fund.
- (10) Taking into account the 1,800,000 H Shares and 7,200,000 H Shares held by OrbiMed Partners Master Fund Limited and Worldwide Healthcare Trust PLC, respectively, pursuant to the cornerstone investment agreement as described under the section headed “Cornerstone Investors” in the Prospectus, OrbiMed Capital LLC is deemed to be interested in the above H Shares.
- (11) The calculation is based on the percentage of shareholding in a total of 176,000,000 Shares, which consist of 71,786,608 Domestic Shares and 104,213,392 H Shares as at 30 June 2025.

SUPPLEMENTARY INFORMATION

Interests of Substantial Shareholders of other members of the Group

Name	Member of the Group	Nature of Interest	Approximate percentage held by the substantial shareholder
Jiang Xiannan (姜賢男)	Shanghai Pukon Medical Instruments Co., Ltd. (上海璞康醫療器械有限公司)	Beneficial owner	15.0%
Chen Linling (陳臨凌)	Shanghai Healing Medical Instruments Co., Ltd. (上海翰凌醫療器械有限公司)	Beneficial owner	24.5%
Liang Dongke (梁棟科)	Shanghai Puhui Medical Instruments Co., Ltd. (上海璞慧醫療器械有限公司) ("Shanghai Puhui")	Beneficial owner	21.0%
Ningbo Youtuo Enterprise Management Partnership (Limited Partnership)* (寧波優拓企業管理合夥企業(有限合夥))	Shanghai Puhui	Beneficial owner	20.0%
Sun Peng (孫鵬)	Shanghai Qimu Medical Instruments Co., Ltd. (上海七木醫療器械有限公司)	Beneficial owner	10.0%
Lin Peng (林鵬)	Shanghai Pumei Medical Instruments Co., Ltd. (上海璞鎂醫療器械有限公司)	Beneficial owner	30.0%
Hengyi Enterprise Management (Wei Fang) Center (Limited Partnership)* (恆熠企業管理(淮坊)中心(有限合夥))	Shanghai Pulin Medical Instruments Co., Ltd. (上海璞霖醫療器械有限公司)	Beneficial owner	35.0%
Ningbo Liufang Enterprise Management Partnership (Limited Partnership)* (寧波六方企業管理合夥企業(有限合夥)) ("Ningbo Liufang")	Shanghai Puyue Medical Instruments Co., Ltd. (上海璞躍醫療器械有限公司)	Beneficial owner	40.0%
Ningbo Liufang	Zhuhai Puyue Medical Instruments Co., Ltd.* (珠海璞躍醫療器械有限公司)	Interest of controlled corporation	40.0%
Xie Guozhu (謝國柱)	Shandong Insant New Materials Co., Ltd. (山東瑛盛新材料有限公司) ("Insant New Materials")	Beneficial owner	29.0%
Yang Tao (楊濤)	Insant New Materials	Beneficial owner	20.0%
Shanghai Shurui Technology Co., Ltd.* (上海曙瑞科技有限公司)	Shanghai Taijiarui Medical Technology Co., Ltd.* (上海泰嘉瑞醫療科技有限公司) ("Shanghai Taijiarui")	Beneficial owner	39.0%

SUPPLEMENTARY INFORMATION

Name	Member of the Group	Nature of Interest	Approximate percentage held by the substantial shareholder
Ningbo Zhuoguang Enterprise Management Partnership (Limited Partnership)* (寧波卓廣企業管理合夥企業(有限合夥))	Shanghai Taijiarui	Beneficial owner	10.0%
Song Yuan (宋媛)	Shanghai INT Life Co., Ltd.* (上海瑛泰昇活商貿有限公司)	Beneficial owner	30.0%
Zhuhai Lingfeng Zunhe Investment Partnership Enterprise (Limited Partnership)* (珠海凌峰尊合投資合夥企業(有限合夥))	Zhuhai Purui Intelligent Manufacturing Co., Ltd.* (珠海璞瑞智能制造有限公司)	Beneficial owner	40.0%
Song Yuan (宋媛)	Shanghai INT Investment Management Co., Ltd.* (上海瑛泰投資管理有限公司) ("Shanghai INT Investment Management")	Beneficial owner	10.0%
Lin Sen (林森)	Shanghai INT Investment Management	Beneficial owner	10.0%
Wang Ruiqin (王瑞琴)	Shanghai INT Investment Management	Beneficial owner	10.0%
Shanghai Chenyue Weixin Medical Technology Co., Ltd.* (上海辰躍維新醫療科技有限公司) ("Chenyue Weixin")	Hangzhou Weiqiang Medical Technology Co., Ltd.* (杭州唯強醫療科技有限公司) ("Hangzhou Weiqiang")	Beneficial owner	31.4%
Endonom Medical (Hong Kong) Co., Limited ("Endonom Medical")	Hangzhou Weiqiang	Beneficial owner	13.9%
Chenyue Weixin	Hangzhou Weixi Medical Technology Co., Ltd.* (杭州唯浙醫療科技有限公司) ("Hangzhou Weixi")	Interest of controlled corporation	31.4%
Endonom Medical	Hangzhou Weixi	Interest of controlled corporation	13.9%

Save as disclosed above, as of 30 June 2025, to the best knowledge of the Directors, no other person had, or were deemed or taken to have interest or short position in the Shares or underlying Shares which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the registry kept by the Company pursuant to Section 336 of the SFO.

SUPPLEMENTARY INFORMATION

DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

No arrangement has been made by the Company or any of its subsidiaries for any Director or Supervisor to acquire benefits by means of the acquisition of Shares in or debentures of the Company or any other body corporate, and no rights to any share capital or debentures of the Company or any other body corporate were granted to any Director, Supervisor, or their respective spouse or children under 18 years of age, nor were any such rights exercised during or at the end of the Reporting Period.

SHARE INCENTIVE SCHEME

The Board resolved to adopt, and the Shareholders approved, the Share Incentive Scheme of granting no more than 5,000,000 Domestic Shares in the form of restricted share (“RS”) to no more than 100 employees of the Group. 2,500,000 Domestic Shares were allotted and issued to each of Dr. Liang Dongke and Share Incentive Platforms for administration of the Share Incentive Scheme. Grantees of the RS (the “Grantees”) (other than Dr. Liang Dongke) were admitted as limited partners of the Share Incentive Platforms, which are Jingning Int Chuangyuan Enterprise Management Partnership (Limited Partnership)* (景寧瑛泰創源企業管理合夥企業(有限合夥)) (“Int Chuangyuan”) and Jingning Int Chuangqi Enterprise Management Partnership (Limited Partnership)* (景寧瑛泰創啟企業管理合夥企業(有限合夥)) (“Int Chuangqi”).

The Remuneration Committee may select eligible grantees amongst the Directors, Supervisors, senior management of the Group, and employees, which is subject to review and approval by the Board and the Supervisory Committee. The RS were granted to the Grantees at a price equivalent to RMB12.0 per Share. The Grantees shall be subject to certain vesting conditions and a lock-up period of sixty months from (a) the date of allotment of Shares to the Share Incentive Platforms or (b) the date of grant of the RS to the Grantee, whichever is later.

The Company has previously applied to the CSRC for allotment of 2,000,000 Domestic Shares (the “First Installment”) to Dr. Liang Dongke and the Share Incentive Platforms, namely Int Chuangyuan and Int Chuangqi pursuant to the Share Incentive Scheme. On 13 May 2022, the Company completed the registration for the First Installment with the CSDC. The total consideration for the grant price of RMB12.0 per Share for the First Installment has been paid by Dr. Liang Dongke and the Share Incentive Platforms.

The Company has applied to the CSRC and has received the CSRC’s approval dated 17 October 2023 for the allotment and issuance of the remaining 3,000,000 Award Shares under the Share Incentive Scheme. For more details of the Share Incentive Scheme, please refer to the Company’s announcements dated 21 September 2020, 17 May 2021, 19 August 2021, 16 May 2022 and 24 October 2023 and the circulars dated 6 November 2020 and 16 April 2021.

On 30 December 2022, the Board resolved to make certain amendments to the Share Incentive Scheme in light of the Company’s proposed adjustment to the performance target provision of the Share Incentive Scheme taking into account the ongoing impact of COVID-19 on the production and operation of the Company in 2022, and the amendments to the Listing Rules to implement the proposals of the “Consultation Conclusions on Proposed Amendments to Listing Rules relating to Share Schemes of Listed Issuers and Housekeeping Rule Amendment” published by the Stock Exchange on 29 July 2022 (the “New Chapter 17”), subject to the Shareholders’ approval. The Board proposed to seek approval from the Shareholders, to among other things, (i) amend the performance target provision of the Share Incentive Scheme in order to extend the Review Period (as defined under the Share Incentive Scheme) to the fourth financial year ended 31 December 2023 and (ii) bring the Share Incentive Scheme in alignment with the New Chapter 17 of the Listing Rules and make certain minor housekeeping amendments to the

SUPPLEMENTARY INFORMATION

Share Incentive Scheme for the purpose of clarifying existing practice and making consequential amendments (the **"Amendments to the Share Incentive Scheme"**). The Amendments to the Share Incentive Scheme was approved by the Shareholders at the annual general meeting held on 18 May 2023. The Board proposed to seek approval from the Shareholders to amend the scheme terms of the Share Incentive Scheme are silent as to whether the RS lapsed due to voluntary withdrawal by the relevant grantees due to inability to pay purchase price notwithstanding of achieving the performance assessment targets and meeting the vesting conditions should be classified as "cancelled" or "lapsed". The scheme terms of the Share Incentive Scheme are also vague as to the repurchase price payable by the general partner of the Share Incentive Platforms in order to repurchase the RS lapsed due to voluntary withdrawal by the relevant grantees due to inability to pay purchase price (the **"Amendments to Scheme Terms"**). The Amendments to Scheme Terms was approved by the Shareholders at the AGM held on 23 May 2025. For more details, please refer to the Company's announcements dated 30 December 2022, 18 May 2023, 4 December 2024 and 23 May 2025, the circulars dated 14 April 2023 and 8 May 2025 and the supplemental circular dated 3 May 2023.

The principal terms of the Share Incentive Scheme are set out below:

Purpose of the Share Incentive Scheme

The purpose of the Share Incentive Scheme is to further establish and improve the incentive mechanism of the Company, fully mobilize the enthusiasm of the Company's management personnel and core backbone personnel at all levels, continuously introduce various excellent technological and senior management talents, and promote the realization of the Company's overall strategic goals at the same time, under the premise of fully protecting the interests of shareholders and pursuant to the current relevant laws and regulations, the Listing Rules and the Articles etc.

Lock-up Period

RS granted under the Share Incentive Scheme are subject to a lock-up period of 60 months. The lock-up period for the 2,000,000 Domestic Shares granted in the first phase of the Share Incentive Scheme is 60 months commencing from the date of completion of the registration of the granted shares with the CSDC. The lock-up period for the 3,000,000 Shares granted subsequently is the same as that of the first grant, and the unlocking date is the same with that of the first grant.

Maximum Entitlement of Each Grantee

Where any grant of Domestic Shares to a Grantee would result in the Shares issued and to be issued in respect of all options and awards granted to such grantee (excluding any options and awards lapsed in accordance with the terms of the Share Incentive Scheme or any other share schemes) in the 12-month period up to and including the date of such grant representing in aggregate over 1% of the total issued Shares, such grant must be separately approved by the Shareholders at the general meeting, with such grantee and his/her close associates (or associate if the grantee is a connected person) abstaining from voting, and the Company must send a circular to the Shareholders.

The Board proposed to seek approval from the Shareholders to increase Dr. Liang's individual limit (through the Share Incentive Platforms) from 83,400 RS to 1,000,000 RS (**"Dr. Liang's Individual Limit"**). Dr. Liang's Individual Limit was approved by the Shareholders at the AGM held on 23 May 2025. For more details, please refer to the Company's announcements dated 4 December 2024, 13 December 2024 and 23 May 2025, and the circular dated 8 May 2025.

SUPPLEMENTARY INFORMATION

Determination Basis of Grant Price

On the basis of completion of financial auditing and assets evaluation, and under the principle that the issuance price shall not be lower than the net assets per share of the Company as of 31 December 2019, taking into account the actual cost factors such as amount of capital contribution required to be paid by the grantee in order to acquire the relevant RS and tax obligations etc., the Company decided to determine the grant price of the RS to be RMB12.0 per Share, and calculate the price of each partnership interest based on the total interest of the employee shareholding platform.

Remaining Life of the Share Incentive Scheme

The Share Incentive Scheme will expire at the 10th anniversary of the date when the Share Incentive Scheme was approved at the extraordinary general meeting of the Company on 17 December 2020. As at 30 June 2025, the remaining life of the Share Incentive Scheme is approximately 5.5 years.

Total Number of Shares Available for Issue

As at the date of this interim report, the total number of Shares available for issue under the Share Incentive Scheme was nil, representing 0.00% of the issued Shares (excluding treasury shares) of the Company, because all 5,000,000 Domestic Shares in the form of RS under the Share Incentive Scheme have been fully granted and issued.

Details of the RS granted under the Share Incentive Scheme are set out below:

Name of Grantee	Category of Grantee	Date of Grant	Lock-up Period ⁽¹⁾	Exercise Period	Vesting Period	Number of RS					As at 30 June 2025	Grant price	Fair Value of the Award as at the Date of Grant
						As at 1 January 2025	Granted during the Reporting Period	Attributed during the Reporting Period	Cancelled during the Reporting Period	Lapsed/ Forfeited during the Reporting Period			
Dr. Liang Dongke	Director and general manager	19 August 2021	60 months from 13 May 2022	12 months after obtaining the CSRC approval	Nil	3,384,300	Nil	Nil	Nil	Nil	3,384,300	RMB12.0	RMB14.81
Mr. Lin Sen	Director	19 August 2021	60 months from 13 May 2022	12 months after obtaining the CSRC approval	Nil	141,600	Nil	Nil	Nil	Nil	141,600	RMB12.0	RMB14.81
Dr. Song Yuan	Director	19 August 2021	60 months from 13 May 2022	12 months after obtaining the CSRC approval	Nil	141,600	Nil	Nil	Nil	Nil	141,600	RMB12.0	RMB14.81
Mr. Wang Ruiqin	Director	19 August 2021	60 months from 13 May 2022	12 months after obtaining the CSRC approval	Nil	100,000	Nil	Nil	Nil	Nil	100,000	RMB12.0	RMB14.81
Others	Employees	19 August 2021	60 months from 13 May 2022	12 months after obtaining the CSRC approval	Nil	1,232,500	Nil	Nil	Nil	Nil	1,232,500	RMB12.0	RMB14.81

SUPPLEMENTARY INFORMATION

Note:

- (1) Pursuant to the Share Incentive Scheme, during the lock-up period, if the domestic shares of the Company are listed on a stock exchange, the shares or partnership interest acquired by the grantees through the Share Incentive Scheme shall not be transferred upon the listing of the domestic shares of the Company, and the lock-up period will be extended until the expiry of 36 months of the listing of the Company's domestic shares (or the lock-up period after the listing of the domestic shares pursuant to the latest laws and regulations at that time).

As at 1 January 2025 and at 30 June 2025, the total number of awards available for grant under the scheme mandate was nil and nil, respectively, because all 5,000,000 Domestic Shares in the form of RS under the Share Incentive Scheme had been fully granted and issued.

The number of Shares that may be issued in respect of awards granted under all schemes of the Company during the Reporting Period divided by the weighted average number of Shares in issue (excluding treasury shares) for the Reporting Period is 0.00%.

2023 SHARE INCENTIVE SCHEME

On 29 August 2023, the Board resolved to adopt the 2023 Share Incentive Scheme of granting no more than 5,000,000 Domestic Shares in the form of RS representing 2.98% of the Company's then total issued Shares of 168,000,000 Shares and 2.84% of the total Shares after the Company completes the aforesaid direct issuance of 5,000,000 Domestic Shares (including 3,000,000 Shares under the Share Incentive Scheme are issued on 6 November 2023). The grantees of the 2023 Share Incentive Scheme include certain Directors and senior management of the Company, general manager and core management personnel of the subsidiaries of the Company. The Shareholders approved the 2023 Share Incentive Scheme at the extraordinary general meeting of the Company held on 19 December 2023. For further details, please refer to the Company's announcements dated 29 August 2023, 24 November 2023 and 29 November 2023, the circular dated 15 October 2023 and the supplemental circular dated 29 November 2023.

The Company has applied to the CSRC and has received the CSRC's approval dated 13 March 2024 for the allotment and issuance of 5,000,000 new Domestic Shares under the 2023 Share Incentive Scheme. For more details, please refer to the Company's announcement dated 15 March 2024.

The Board proposed to seek approval from the Shareholders to amend the scheme terms of the 2023 Share Incentive Scheme are silent as to whether the RS lapsed due to voluntary withdrawal by the relevant grantees due to inability to pay purchase price notwithstanding of achieving the performance assessment targets and meeting the vesting conditions should be classified as "cancelled" or "lapsed" (the "**Amendments to 2023 Share Incentive Scheme**"). The Amendments to 2023 Share Incentive Scheme was approved by the Shareholders at the AGM held on 23 May 2025. For more details, please refer to the Company's announcements dated 4 December 2024 and 23 May 2025 and the circular dated 8 May 2025.

The principal terms of the 2023 Share Incentive Scheme are set out below:

Purpose of the 2023 Share Incentive Scheme

The purpose of the 2023 Share Incentive Scheme is to further establish and improve the incentive mechanism of the Group, fully mobilize the enthusiasm of the Group's management personnel, continuously introduce various excellent senior management talents and promote the realization of the Group's overall strategic goals under the premise of fully protecting the interests of Shareholders and pursuant to the current relevant laws and regulations, the Listing Rules and the Articles etc.

SUPPLEMENTARY INFORMATION

Lock-up Period

The shares obtained by the employees under the 2023 Share Incentive Scheme will be subject to a lock-up period of 60 months (the **"Lock-up Period"**) commencing from the date of grant as approved by the Board. If the 2023 Share Incentive Scheme will adopt the approach of issuance in installments, then the Shares to be issued in subsequent installments will be subject to the same Lock-up Period as that of the shares to be issued in the first installment. The Lock-up Period aligns with the Scheme's purpose of promoting the realization of the Company's overall strategic goals and protecting the interests of shareholders.

Maximum Entitlement of Each Grantee

Where any grant of Domestic Shares to a Grantee would result in the Shares issued and to be issued in respect of all options and awards granted to such grantee (excluding any options and awards lapsed in accordance with the terms of the 2023 Share Incentive Scheme or any other share schemes) in the 12-month period up to and including the date of such grant representing in aggregate over 1% of the total issued Shares, such grant must be separately approved by the Shareholders at the general meeting, with such grantee and his/her close associates (or associate if the grantee is a connected person) abstaining from voting, and the Company must send a circular to the Shareholders.

Where any grant of Domestic Shares to a grantee that is a Director (other than an independent non-executive Director) or chief executive of the Company, or any of their associates would result in the Shares issued and to be issued in respect of all awards granted (excluding any awards lapsed in accordance with the terms of the scheme) to such person in the 12-month period up to and including the date of such grant, representing in aggregate over 0.1% of the relevant class of Shares in issue, such further grant of awards must be approved by the Shareholders at general meeting, with such grantee, his/her associates and all core connected persons of the Company abstaining from voting in favour at such general meeting.

Vesting Period

The restricted shares granted under the 2023 Share Incentive Scheme will vest immediately on the date of grant. The scheme does not impose a vesting period with regard to the restricted shares granted under the 2023 Share Incentive Scheme in order to provide more incentives for them to achieve their respective performance targets and make long-term contribution to the development of the Company. Considering that such vesting arrangements are appropriate for retaining, incentivizing, rewarding, remunerating and compensating valuable employees and the restricted shares granted under the 2023 Share Incentive Scheme will be subject to a total vesting and holding period (i.e., the Lock-up Period) of more than 12 months, the Remuneration Committee is of the view that such arrangement with no vesting period is justifiable and aligns with the purposes of the scheme.

Determination Basis of Grant Price

On the basis of completion of financial auditing and assets evaluation, and under the principle that the issuance price shall not be lower than the net assets per share of the Company as of 31 December 2022, taking into account the actual cost factors such as amount of capital contribution required to be paid by the grantee in order to acquire the relevant restricted shares and tax obligations etc., the Company decided to determine the grant price of the restricted shares to be RMB12.0 per Domestic Share, and calculate the price of each partnership interest based on the total interest of the employee shareholding platform.

SUPPLEMENTARY INFORMATION

Remaining Life of the 2023 Share Incentive Scheme

The validity period of the 2023 Share Incentive Scheme commences from the date when it is approved at the extraordinary general meeting on 19 December 2023 to the date when all RS granted under the 2023 Share Incentive Scheme are unlocked or repurchased and cancelled, the longest period of which shall not exceed ten (10) years. As at 30 June 2025, the remaining life of the 2023 Share Incentive Scheme is approximately 8.5 years.

Total Number of Shares Available for Issue

As at the date of this interim report, the total number of Shares available for issue under the 2023 Share Incentive Scheme was nil, representing 0.00% of the issued Shares (excluding treasury shares) of the Company because all 5,000,000 Domestic Shares in the form of RS under the 2023 Share Incentive Scheme have been fully granted and issued.

Details of the RS granted under the 2023 Share Incentive Scheme are set out below:

Name of Grantee	Category of Grantee	Date of Grant	Lock-up period	Exercise Period	Vesting Period	As at 1 January 2025	Granted during the Reporting Period	Attributed during the Reporting Period	Cancelled during the Reporting Period	Lapsed/ Forfeited during the Reporting Period	As at 30 June 2025	Grant price	Fair Value of the Award as at the Date of Grant
Dr. Liang Dongke	Director and general manager	19 March 2024	60 months from the date of grant	12 months after obtaining the CSRC approval	Nil	1,760,000	Nil	Nil	Nil	Nil	1,760,000	RMB12.0	RMB16.85
Mr. Lin Sen	Director	19 March 2024	60 months from the date of grant	12 months after obtaining the CSRC approval	Nil	300,000	Nil	Nil	Nil	Nil	300,000	RMB12.0	RMB16.85
Dr. Song Yuan	Director	19 March 2024	60 months from the date of grant	12 months after obtaining the CSRC approval	Nil	300,000	Nil	Nil	Nil	Nil	300,000	RMB12.0	RMB16.85
Mr. Wang Ruiqin	Director	19 March 2024	60 months from the date of grant	12 months after obtaining the CSRC approval	Nil	100,000	Nil	Nil	Nil	Nil	100,000	RMB12.0	RMB16.85
Others	Employees	19 March 2024	60 months from the date of grant	12 months after obtaining the CSRC approval	Nil	2,540,000	Nil	Nil	Nil	Nil	2,540,000	RMB12.0	RMB16.85

As at 1 January 2025 and 30 June 2025, the total number of awards available for grant under the scheme mandate was nil and nil, respectively, because all 5,000,000 Domestic Shares in the form of RS under the 2023 Share Incentive Scheme had been fully granted and issued.

The number of Shares that may be issued in respect of awards granted under all schemes of the Company during the Reporting Period divided by the weighted average number of Shares in issue (excluding treasury shares) for the Reporting Period is 0.00%.

SUPPLEMENTARY INFORMATION

H SHARE AWARD AND TRUST SCHEME

References are made to the announcements of the Company dated 18 March 2022 and 16 May 2022 and the circular of the Company dated 11 April 2022 in relation to, among others, the adoption of the H Share Award and Trust Scheme. The adoption of H Share Award and Trust Scheme was approved by the Shareholders at the Company's annual general meeting held on 16 May 2022. For the principal terms of the H Share Award and Trust Scheme, please refer to the circular of the Company dated 11 April 2022. The H Share Award and Trust Scheme involves no issue of new shares or granting of option for any new securities of the Company. The H Share Award and Trust Scheme constitutes a share scheme involving existing shares under Chapter 17 of the Listing Rules as effective since 1 January 2023.

During the Reporting Period, no H Shares were repurchased by the trustee of the H Share Award and Trust Scheme (during the year ended 31 December 2024: 800,000 H Shares) on the Stock Exchange to satisfy the grant of awards pursuant to the H Share Award and Trust Scheme. No awards was granted as at 30 June 2025.

The principal terms of the H Share Award and Trust Scheme are set out below:

The purposes of the H Share Scheme are: (i) to attract, motivate and retain skilled and experienced personnel to strive for the future development and expansion of the Group by providing them with the opportunity to own equity interests in the Company; (ii) to deepen the reform on the Company's remuneration system and to develop and constantly improve the interests balance mechanism among the Shareholders, the operational and executive management; and (iii) to (a) recognize the contributions of the leadership of the Company including the Directors; (b) encourage, motivate and retain the leadership of the Company whose contributions are beneficial to the continual operation, development and long-term growth of the Group; and (c) provide additional incentive for the leadership of the Company and long standing employee by aligning the interests of the leadership of the Company to those of the Shareholders and the Group as a whole.

Eligible participant who may participate in the H Share Scheme include any full-time PRC or non-PRC employee of any members of the Group, who is a Director (other than independent non-executive Directors), Supervisor, senior management, key operating team member, employee, or, a consultant of the Group.

Subject to the H Share Scheme Rules, the maximum number of H Shares that will be acquired by the Trustee through on-market transactions from time to time at the prevailing market price is 10,420,000 H Shares, which accounts for approximately 5.92% of the Company's total issued Shares (excluding treasury shares) as at the date of this interim report.

Upon approval by the Board or the delegatee, and subject to the vesting conditions set out in the H Share Scheme Rules, all awards under the H Share Scheme shall be vested in multiple tranches as specified in the award letter. The specific commencement and duration of each vesting period and the actual vesting amount of the award granted to a selected participant for the respective vesting periods shall be specified in the award letter approved by the Board or the delegatee.

SUPPLEMENTARY INFORMATION

If the award is vested in the form of award shares, the selected participant shall assume the grant cost for accepting the award shares, namely the grant cost (the product of the grant price of the award shares on the grant date multiplied by the number of award shares granted to a selected participant by the Board of Delegatee (subject to the final determination by the Board or the delegatee), shall be deducted from the actual selling price of the award shares.

The H Share Award and Trust Scheme will expire on the 10th anniversary of 16 May 2022 when it was adopted at the annual general meeting of the Company held on 16 May 2022. As at 30 June 2025, the remaining life of the H Share Award and Trust Scheme is approximately 6.5 years.

MATERIAL EVENTS AFTER THE REPORTING PERIOD

Establishment of Huaige Guangtai Fund

On 6 August 2025, the Company conditionally entered into a partnership agreement with Ningbo Huaige Health Investment Management Partnership Enterprise (Limited Partnership)* (寧波懷格健康管理合夥企業(有限合夥)), (as the general partner and the fund manager) and other limited partners (as the limited partners) in relation to the establishment of, and investment in Ningbo Huaige Guangtai Equity Investment Partnership Enterprise (Limited Partnership)* (寧波懷格廣泰股權投資合夥企業(有限合夥)) (the “**Huaige Guangtai Fund**”). The Company shall participate in the Huaige Guangtai Fund as a limited partner and will make a total capital commitment of RMB110.0 million, among which the initial capital contribution is RMB50.0 million. Detailed information is disclosed in the Company’s announcement dated 6 August 2025.

Save as disclosed above, there were no other material events after the Reporting Period.

By order of the Board
Shanghai INT Medical Instruments Co., Ltd.*
上海瑛泰醫療器械股份有限公司
Dr. Liang Dongke
Chairman

Shanghai, the PRC
28 August 2025

INDEPENDENT AUDITOR'S REVIEW REPORT



Review report to the board of directors of Shanghai INT Medical Instruments Co., Ltd.

(Incorporated in the People's Republic of China with limited liability)

INTRODUCTION

We have reviewed the interim financial report set out on pages 34 to 62 which comprises the consolidated statement of financial position of Shanghai INT Medical Instruments Co., Ltd. (the “**Company**”) as of 30 June 2025 and the related consolidated statement of profit or loss, statement of profit or loss and other comprehensive income and statement of changes in equity and condensed consolidated cash flow statement for the six-month period then ended and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of an interim financial report to be in compliance with the relevant provisions thereof and Hong Kong Accounting Standard 34, *Interim financial reporting*, issued by the Hong Kong Institute of Certified Public Accountants. The directors are responsible for the preparation and presentation of the interim financial report in accordance with Hong Kong Accounting Standard 34.

Our responsibility is to form a conclusion, based on our review, on the interim financial report and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the Hong Kong Institute of Certified Public Accountants. A review of the interim financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial report as at 30 June 2025 is not prepared, in all material respects, in accordance with Hong Kong Accounting Standard 34, *Interim financial reporting*.

KPMG

Certified Public Accountants

8th Floor, Prince's Building
10 Chater Road
Central, Hong Kong

28 August 2025

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

for the six months ended 30 June 2025 — unaudited
(Expressed in Renminbi Yuan)

	Note	Six months ended 30 June	
		2025 RMB'000	2024 RMB'000
Revenue	3	461,075	392,322
Cost of sales		(190,414)	(145,554)
Gross profit		270,661	246,768
Other income	4	30,468	23,941
Distribution costs		(41,528)	(33,607)
Administrative expenses		(64,918)	(55,219)
Research and development expenses		(70,237)	(70,754)
(Provision)/reversal of impairment losses on trade and other receivables		(239)	652
Profit from operations		124,207	111,781
Finance costs	5(a)	(2,915)	(1,032)
Share of loss of an associate		(585)	—
Profit before taxation	5	120,707	110,749
Income tax	6	(18,271)	(11,571)
Profit for the period		102,436	99,178
Attributable to:			
Equity shareholders of the Company		98,528	100,538
Non-controlling interests		3,908	(1,360)
Profit for the period		102,436	99,178
Earnings per share (RMB)	7		
Basic (RMB)		0.57	0.58
Diluted (RMB)		0.57	0.58

The notes on pages 40 to 62 form part of this interim financial report.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

for the six months ended 30 June 2025 — unaudited
(Expressed in Renminbi Yuan)

	Six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
Profit for the period	102,436	99,178
Other comprehensive income for the period (after tax and reclassification adjustments)		
Item that will be reclassified subsequently to profit or loss:		
Exchange differences on translation of financial statements of an overseas subsidiary	(569)	249
Other comprehensive income for the period	(569)	249
Total comprehensive income for the period	101,867	99,427
Attributable to:		
Equity shareholders of the Company	97,959	100,787
Non-controlling interests	3,908	(1,360)
Total comprehensive income for the period	101,867	99,427

The notes on pages 40 to 62 form part of this interim financial report.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

at 30 June 2025 — unaudited
(Expressed in Renminbi Yuan)

	Note	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Non-current assets			
Property, plant and equipment	8	840,575	811,263
Intangible assets	9	422,777	168,739
Right-of-use assets		116,985	105,396
Goodwill	17	306,100	—
Interests in associates		—	585
Certificate of deposits	14	10,216	40,106
Other non-current assets	10	15,013	52,674
Financial assets measured at fair value through profit or loss ("FVPL")	13	267,582	158,615
Deferred tax assets		28,533	30,370
		2,007,781	1,367,748
Current assets			
Inventories	11	197,456	162,339
Trade and other receivables	12	124,196	118,881
Other current assets		56,833	56,399
Financial assets measured at FVPL	13	—	30,000
Cash and cash equivalents	14	480,212	521,954
Certificate of deposits and restricted bank deposits	14	10,641	2,560
		869,338	892,133
Current liabilities			
Trade and other payables	15	205,623	163,740
Contract liabilities		24,316	18,751
Loans and borrowings	16	373,472	227,261
Lease liabilities		9,272	900
Deferred income		2,434	2,290
Current taxation		14,927	21,514
Other current liabilities	17	65,493	—
		695,537	434,456
Net current assets		173,801	457,677
Total assets less current liabilities		2,181,582	1,825,425

The notes on pages 40 to 62 form part of this interim financial report.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

at 30 June 2025 — unaudited
(Expressed in Renminbi Yuan)

	Note	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Non-current liabilities			
Loans and borrowings	16	165,464	—
Lease liabilities		21,648	15,524
Deferred income		21,987	23,409
Deferred tax liabilities		13,109	—
		222,208	38,933
NET ASSETS		1,959,374	1,786,492
CAPITAL AND RESERVES	18		
Share capital		176,000	176,000
Reserves		1,699,900	1,598,227
Total equity attributable to equity shareholders of the Company		1,875,900	1,774,227
Non-controlling interests		83,474	12,265
TOTAL EQUITY		1,959,374	1,786,492

Approved and authorised for issue by the board of directors on 28 August 2025.

LIANG DONG KE

Director

LIN SEN

Director

(Company Stamp)

The notes on pages 40 to 62 form part of this interim financial report.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the six months ended 30 June 2025 — unaudited
(Expressed in Renminbi Yuan)

Note	Attributable to equity shareholders of the Company						Total	Non-controlling interests	Total equity
	Share capital	Treasury shares	Capital reserve	Statutory surplus reserve	Exchange reserve	Retained profits			
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Balance at 1 January 2024	171,000	(21,259)	990,808	81,593	1,191	425,908	1,649,241	29,137	1,678,378
Changes in equity for the six months ended 30 June 2024									
Profit/(loss) for the period	—	—	—	—	—	100,538	100,538	(1,360)	99,178
Other comprehensive income	—	—	—	—	249	—	249	—	249
Equity settled share-based payments	—	—	2,619	—	—	—	2,619	189	2,808
Subscription of restricted shares 18(a)	5,000	—	55,000	—	—	—	60,000	—	60,000
Acquisition of interests in subsidiaries	—	—	(67,958)	—	—	—	(67,958)	(11,015)	(78,973)
Dividends to holders of non-controlling interests	—	—	—	—	—	—	—	(4,500)	(4,500)
Repurchase of shares for share award scheme 18(b)	—	(18,919)	—	—	—	—	(18,919)	—	(18,919)
Dividends approved in respect of previous year 18(c)	—	—	—	—	—	(47,520)	(47,520)	—	(47,520)
Dividends received by treasury share holders	—	—	—	—	—	405	405	—	405
Balance at 30 June 2024	176,000	(40,178)	980,469	81,593	1,440	479,331	1,678,655	12,451	1,691,106
Balance at 1 July 2024	176,000	(40,178)	980,469	81,593	1,440	479,331	1,678,655	12,451	1,691,106
Changes in equity for the six months ended 31 December 2024									
Profit/(loss) for the period	—	—	—	—	—	91,376	91,376	(506)	90,870
Other comprehensive income	—	—	—	—	534	—	534	—	534
Equity-settled share-based payment	—	—	3,662	—	—	—	3,662	320	3,982
Appropriation for surplus reserve	—	—	—	6,617	—	(6,617)	—	—	—
Balance at 31 December 2024	176,000	(40,178)	984,131	88,210	1,974	564,090	1,774,227	12,265	1,786,492
Balance at 31 December 2024 and 1 January 2025	176,000	(40,178)	984,131	88,210	1,974	564,090	1,774,227	12,265	1,786,492
Changes in equity for the six months ended 30 June 2025									
Profit for the period	—	—	—	—	—	98,528	98,528	3,908	102,436
Other comprehensive income	—	—	—	—	(569)	—	(569)	—	(569)
Equity settled share-based payments	—	—	3,714	—	—	—	3,714	319	4,033
Capital injection from non-controlling interests 18(d)	—	—	—	—	—	—	—	59,221	59,221
Acquisition of a subsidiary 17	—	—	—	—	—	—	—	16,761	16,761
Dividends to holders of non-controlling interests	—	—	—	—	—	—	—	(9,000)	(9,000)
Balance at 30 June 2025	176,000	(40,178)	987,845	88,210	1,405	662,618	1,875,900	83,474	1,959,374

The notes on pages 40 to 62 form part of this interim financial report.

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

for the six months ended 30 June 2025 — unaudited
(Expressed in Renminbi Yuan)

	Note	Six months ended 30 June	
		2025 RMB'000	2024 RMB'000
Operating activities			
Cash generated from operations		145,784	130,407
Tax paid		(23,123)	(25,589)
Net cash generated from operating activities		122,661	104,818
Investing activities			
Payment for purchase of property, plant and equipment and intangible assets		(53,840)	(82,276)
Proceeds from sale of property, plant and equipment		314	189
Net cash outflow arising from the acquisition of a subsidiary	17	(245,778)	—
Payment for the investment in unlisted funds		(107,500)	(2,500)
Payment for purchase of financial assets measured at FVPL		(248,000)	—
Proceeds from redemption of financial assets measured at FVPL		278,474	—
Interest received from bank deposits		4,859	3,904
Net decrease of deposit		22,560	—
Net cash used in investing activities		(348,911)	(80,683)
Financing activities			
Capital injection received from non-controlling interests	18(d)	59,221	—
Issuance of restricted shares		—	60,000
Proceeds from loans and borrowings		405,080	52,500
Repayments of loans and borrowings		(265,186)	(80,000)
Interest of loans and borrowings paid		(2,519)	(733)
Payment for capital element of lease liabilities		(1,657)	—
Dividends paid to equity shareholders of the Company	18(c)	—	(47,115)
Dividends paid to holders of non-controlling interests		(9,000)	(4,500)
Payment for the acquisition of interests in subsidiaries		—	(78,973)
Payment for repurchase of own shares of the Company	18(b)	—	(18,919)
Net cash generated from/(used in) financing activities		185,939	(117,740)
Net decrease in cash and cash equivalents		(40,311)	(93,605)
Cash and cash equivalents at 1 January	14	521,954	423,668
Effects of foreign exchange rates changes		(1,431)	577
Cash and cash equivalents at 30 June	14	480,212	330,640

The notes on pages 40 to 62 form part of this interim financial report.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

1 BASIS OF PREPARATION

This interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with Hong Kong Accounting Standard (“HKAS”) 34, *Interim financial reporting*, issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”). It was authorised for issue on 28 August 2025.

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2024 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2025 annual financial statements. Details of any changes in accounting policies are set out in note 2.

The preparation of the interim financial report in conformity with HKAS34 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of Shanghai INT Medical Instruments Co., Ltd. (the “**Company**”) and its subsidiaries (together, the “**Group**”) since the 2024 annual financial statements. The condensed consolidated interim financial statements and notes thereon do not include all of the information required for a full set of financial statements prepared in accordance with Hong Kong Financial Reporting Standards issued by HKICPA (“**HKFRS Accounting Standards**”).

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the HKICPA. KPMG’s independent review report to the Board of Directors is included on page 33.

The financial information relating to the financial year ended 31 December 2024 that is included in the interim financial report as comparative information does not constitute the Company’s statutory annual consolidated financial statements for that financial year but is derived from those financial statements. The Company’s annual consolidated financial statements for the year ended 31 December 2024 are available from the Company’s registered office. The auditors have expressed an unqualified opinion on those financial statements in their report dated 18 March 2025.

2 CHANGES IN ACCOUNTING POLICIES

The Group has applied the amendments to HKAS 21, *The effects of changes in foreign exchange rates — Lack of exchangeability* issued by the HKICPA to this interim financial report for the current accounting period. The amendments do not have a material impact on this interim report as the Group has not entered into any foreign currency transactions in which the foreign currency is not exchangeable into another currency.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

3 REVENUE AND SEGMENT REPORTING

The Group manages its businesses by divisions, which are organised by business lines. In a manner consistent with the way in which information is reported internally to the Group's most senior executive management for the purposes of resource allocation and performance assessment, the Group has identified one reportable segment, the cardiovascular interventional business, which is primary engaged in sales, manufacture, research and development of cardiovascular interventional medical devices as well as related moulds and accessories. Other segments, which are currently engaged in research and development of other interventional and implantable medical devices, such as neurological interventional medical devices, peripheral vascular interventional medical devices and endocardia implantable medical devices, etc are combined in all other segments.

(a) Disaggregation of revenue

(i) Disaggregation of revenue from contracts with customers by major products is as follows:

	Six months ended 30 June	
	2025 RMB'000	2024 RMB'000
Revenue from contracts with customers within the scope of HKFRS15		
Disaggregated by major products		
— Sales of interventional medical devices		
<i>Cardiovascular devices</i>	292,478	268,414
<i>Neurological, peripheral and other devices</i>	99,888	77,062
Subtotal	392,366	345,476
— Sales of medical accessories	31,412	26,743
— Agent business	32,408	14,818
— Moulds and others	3,154	3,728
	459,340	390,765
Revenue from other source		
Rental income	1,735	1,557
	461,075	392,322

The Group's customer base is diversified. There is no individual customer with whom transactions have exceeded 10% of the Group's revenue for the six months ended 30 June 2025 and 2024.

During the six months ended 30 June 2025 and 2024, the Group recognised its revenue from contract with customers within the scope of HKFRS15 at point in time.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

3 REVENUE AND SEGMENT REPORTING (Continued)

(a) Disaggregation of revenue (Continued)

(ii) Disaggregation of revenue by geographical location of external customers is as follows:

	Six months ended 30 June	
	2025 RMB'000	2024 RMB'000
Chinese Mainland	341,016	279,623
Europe	25,188	28,248
The United States	29,348	21,157
Other countries and regions	65,523	63,294
	461,075	392,322

The geographical location of customers is based on the location at which the customers operate. All of the non-current assets of the Group are physically located in Chinese Mainland.

(b) Segment reporting

(i) Segment results

Information regarding the Group's reportable segments as provided to the Group's most senior executive management for the purposes of resource allocation and assessment of segment performance for the period is set out below:

	Six months ended 30 June 2025		
	Cardiovascular interventional business RMB'000	All others RMB'000	Total RMB'000
Revenue from external customers	392,823	68,252	461,075
Inter-segment revenue	10,170	22,597	32,767
Segment revenue	402,993	90,849	493,842
Segment net profit	91,422	11,297	102,719

	Six months ended 30 June 2024		
	Cardiovascular interventional business RMB'000	All others RMB'000	Total RMB'000
Revenue from external customers	343,842	48,480	392,322
Inter-segment revenue	10,858	21,579	32,437
Segment revenue	354,700	70,059	424,759
Segment net profit	95,487	6,724	102,211

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

3 REVENUE AND SEGMENT REPORTING (Continued)

(b) Segment reporting (Continued)

(ii) Reconciliation of segment profit

	Six months ended 30 June	
	2025 RMB'000	2024 RMB'000
Revenue		
Segment revenue	493,842	424,759
Elimination of inter-segment revenue	(32,767)	(32,437)
Consolidated revenue	461,075	392,322
Profit		
Segment net profit	102,719	102,211
Elimination of inter-segment net profit	(283)	(3,033)
Consolidated net profit	102,436	99,178

4 OTHER INCOME

	Six months ended 30 June	
	2025 RMB'000	2024 RMB'000
Government grants (note)	23,775	7,810
Interest income	5,610	4,248
Net realised and unrealised gains from financial instruments measured at FVPL	1,941	8,131
Foreign exchange (losses)/gains	(739)	2,029
Others	(119)	1,723
	30,468	23,941

Note: Government grants mainly include subsidies received from government for encouragement of research and development projects and compensation on the capital expenditure of medical device production lines. As at the end of reporting period, there was no unfulfilled condition or other contingency attaching to the government grants that had been recognised by the Group.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

5 PROFIT BEFORE TAXATION

Profit before taxation is arrived at after charging/(crediting):

	Six months ended 30 June	
	2025 RMB'000	2024 RMB'000
(a) Finance costs		
Interest on lease liabilities	445	379
Interest on loans and borrowings	2,470	653
	2,915	1,032
(b) Other items		
Depreciation and amortisation		
— property, plant and equipment	37,553	38,287
— right-of-use assets	2,429	1,902
— intangible assets	4,444	1,945
Provision/(reversal) of impairment loss on trade and other receivables	239	(652)
Impairment loss on capitalised development costs	—	620
Provision for write-down of inventories	1,787	700
Research and development costs (<i>note</i>)	91,672	85,931
Less: costs capitalised into intangible assets	(21,435)	(15,177)
	70,237	70,754

Note: During the six months ended 30 June 2025, research and development costs includes depreciation and amortisation costs of RMB7.2 million (six months ended 30 June 2024: RMB7.5 million), which amount is also included in the respective total amounts disclosed separately above.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

6 INCOME TAX

	Six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
Current tax-the People's Republic of China (the "PRC")		
corporate income tax ("CIT")	16,536	10,670
Deferred tax	1,735	901
Total	18,271	11,571

PRC CIT

- (i) Effective from 1 January 2008, under the PRC Corporate Income Tax Law, the PRC statutory income tax rate is 25%. The Group's subsidiaries in the PRC are subject to PRC income tax at 25% unless otherwise specified.

- (ii) High and New Technology Enterprise ("HNTE")

According to the PRC income tax law and its relevant regulations, entities that qualified as HNTE are entitled to a preferential income tax rate of 15%. The Company and certain subsidiaries are qualified as HNTE and are subject to income tax at the rate of 15% for the six months ended 30 June 2025 and 2024.

The 15% preferential tax rate applicable to HNTE is subject to renewal approval jointly by the relevant authorities, upon expiry of the three-year grant period, according to the then prevailing income tax regulations.

- (iii) Small and Micro Enterprise ("SME")

According to the PRC income tax law and its relevant regulations issued in 2019 and renewed policy issued in 2023, entities that qualified as SME are entitled to a preferential income tax rate of 5% for taxable income less than RMB3 million.

During the periods ended 30 June 2025 and 2024, certain subsidiaries of the Group are qualified as small and low profit enterprise and enjoyed a preferential tax rate of 5%, whereas applicable.

- (iv) According to the PRC income tax law and its relevant regulations, an additional 100% of qualified research and development expenses so incurred is allowed to be deducted from taxable income.

HONG KONG PROFIT TAX

During the six months ended 30 June 2025 and 2024, the Company's subsidiary incorporated in Hong Kong is subject to Hong Kong Profits Tax at 8.25% of the taxable profit less than Hong Kong Dollar ("HKD") 2 million or 16.50% of the taxable profit exceeding HKD2 million.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

7 EARNINGS PER SHARE

(a) Basic earnings per share

The calculation of basic earnings per share is based on the adjusted profit attributable to ordinary equity shareholders of the Company of RMB92.9 million (six months ended 30 June 2024: RMB94.8 million) and the weighted average of 164,307,000 ordinary shares (2024: 164,707,000 shares) in issue during the interim period, calculated as follows:

Adjusted profit attributable to equity shareholders of the Company

	Six months ended 30 June	
	2025 RMB'000	2024 RMB'000
Profit attributable to equity shareholders	98,528	100,538
Effect of unvested restricted shares	(5,653)	(5,755)
Adjusted profit attributable to equity shareholders	92,875	94,783

Weighted average number of ordinary shares

	2025 '000	2024 '000
Issued ordinary shares at 1 January	176,000	171,000
Effect of restricted shares issued	—	5,000
Effect of unvested restricted shares	(10,000)	(10,000)
Effect of purchase of own shares	(1,693)	(1,293)
Weighted average number of ordinary shares at 30 June	164,307	164,707

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

7 EARNINGS PER SHARE (Continued)

(b) Diluted earnings per share

The calculation of diluted earnings per share is based on the adjusted profit attributable to equity shareholders of the Company of RMB96.6 million (six months ended 30 June 2024: RMB97.7 million), and the weighted average number of ordinary shares of 170,807,000 (six months ended 30 June 2024: 169,707,000) in issue, calculated as follows.

Adjusted profit attributable to equity shareholders of the Company (diluted)

	Six months ended 30 June	
	2025 RMB'000	2024 RMB'000
Adjusted profit attributable to equity shareholders (basic)	92,875	94,783
Effect of contingently issuable restricted shares	3,675	2,877
Adjusted profit attributable to ordinary equity shareholders (diluted)	96,550	97,660

Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares to assume conversion of outstanding restricted shares, which are dilutive and adjusting the weighted average number of ordinary shares in issue during the interim period, calculated as follows:

Weighted average number of ordinary shares (diluted)

	Six months ended 30 June	
	2025 '000	2024 '000
Weighted average number of ordinary shares in issue for the purpose of basic earnings per share	164,307	164,707
Effect of contingently issuable restricted shares	6,500	5,000
Weighted average number of ordinary shares in issue for the purpose of diluted earnings per share	170,807	169,707

The effect of outstanding employee share purchase plan issued by the subsidiaries is anti-dilutive for the six months ended 30 June 2025 and 2024, therefore is not included in the calculation of diluted earnings per share of the Company.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

8 ACQUISITION OF PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2025, the Group acquired items of property, plant and equipment with a cost of RMB67.2 million (six months ended 30 June 2024: RMB51.5 million), of which RMB18.2 million addition was from business combination as disclosed in note 17.

9 ADDITION OF INTANGIBLE ASSETS

During the six months ended 30 June 2025, the increase in intangible assets amounted to RMB258.5 million (six months ended 30 June 2024: RMB16.1 million) of which RMB236.1 million addition of patent, capitalised development cost and software was from business combination as disclosed in note 17.

10 OTHER NON-CURRENT ASSETS

	30 June 2025 RMB'000	31 December 2024 RMB'000
Prepayment for purchase of property, plant and equipment	10,434	8,448
Investment deposits (Note)	—	38,092
Others	4,579	6,134
Total	15,013	52,674

Note:

During the year ended 31 December 2023, the Company (the “Purchaser”) entered into an acquisition agreement with three individuals (the “Vendors”) and Shanghai Hude Automobile Tensioning Wheel Co., Ltd.* 上海滬德汽車張緊輪有限公司 (“Shanghai Hude”), pursuant to which, amongst others, the Purchaser has agreed to purchase and the Vendors have agreed to sell its entire equity interest in Shanghai Hude at a consideration of RMB32 million, of which its assets mainly consist of a land use right in Shanghai. As at 31 December 2024, the Company had paid RMB27 million. The RMB27 million investment deposit transferred to property, plant and equipment upon the completion of this transaction and all relevant legal process was completed as of 30 June 2025.

On 18 December 2024, the Company entered into an acquisition intention agreement (the “Acquisition Intention Agreement”) with Hangzhou Weiqiang Medical Technology Co., Ltd.* 杭州唯強醫療科技有限公司 (“Hangzhou Weiqiang”) and other four entities (the “Other Target Group Companies”), pursuant to which, the Company has conditionally agreed to acquire the controlling stake with at least 51% equity interest in Hangzhou Weiqiang. In December 2024, the Company paid advance payment of RMB11 million. The transaction has been completed as at 30 June 2025 as disclosed in note 17.

* English translation is for identification purpose only.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

11 INVENTORIES

	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Raw materials	94,839	71,310
Work in progress	35,972	27,039
Finished goods	64,189	63,204
Goods in transit	2,456	786
	197,456	162,339

During six months ended 30 June 2025, RMB1.8 million (six months ended 30 June 2024: RMB0.7 million) has been recognised as a reduction in the amount of inventories recognised as an expense in profit or loss during the period, being the amount of accrual of a write-down of inventories to the estimated net realisable value.

12 TRADE AND OTHER RECEIVABLES

	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Receivables from third parties	86,459	114,809
Receivables from related parties	296	920
Less: losses allowance on trade receivables	(894)	(656)
Trade receivables, net	85,861	115,073
Investment deposits	14,201	496
Subsidy receivable	6,270	–
Other deposits and receivables	17,910	3,357
Less: losses allowance on other receivables	(46)	(45)
Trade and other receivables, net	124,196	118,881

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

12 TRADE AND OTHER RECEIVABLES (Continued)

(a) Ageing analysis

As of the end of the reporting period, the ageing analysis of trade receivables, based on the invoice date and net of loss allowance, is as follows:

	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Within 3 months	78,552	108,452
3 to 6 months	4,138	5,769
6 to 9 months	3,171	852
	85,861	115,073

Trade receivables are generally due within 30 to 90 days from the date of billing. All of the trade and other receivables are expected to be recovered or recognised as expense within one year.

13 FINANCIAL ASSETS MEASURED AT FVPL

	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Non-current portion		
Unlisted units in investment funds (note)		
— managed by Ningbo Huaige Health Investment Management Partnership (Limited Partnership)* (寧波懷格健康投資管理合夥企業(有限合夥))	135,897	133,533
— managed by other third parties fund managers	124,685	18,082
	260,582	151,615
Unlisted equity investment	7,000	7,000
	267,582	158,615
Current portion		
Structured bank deposits	—	30,000

Note: The non-current financial assets measured at FVPL represent investments in units in unlisted funds and a private entity incorporated in the PRC. These investments are primarily engaged or further invested in the life science and healthcare sectors.

* English translation is for identification purpose only.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

14 CASH AND CASH EQUIVALENTS, CERTIFICATE OF DEPOSITS AND RESTRICTED BANK DEPOSITS

(a) Cash and cash equivalents

	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Cash at bank (note)	480,163	521,928
Cash on hand	49	26
Cash and cash equivalents	480,212	521,954

Note: Cash at bank includes deposits placed at banks in the PRC with original maturities of less than three months. Remittance of funds out of Chinese Mainland is subject to relevant rules and regulations of foreign exchange control.

(b) Certificate of deposits and pledged deposits

	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Current portion		
Certificate of deposits (note i)	10,641	—
Restricted bank deposits	—	2,560
	10,641	2,560
Non-current portion		
Certificate of deposits (note ii)	10,216	40,106

Notes:

- (i) This balance represents deposits placed at banks in the PRC with original maturities over three months but within one year.
- (ii) As at 30 June 2025, the non-current portion of deposits placed at banks in the PRC have fixed returns rates ranged from 2.4% and maturity periods of three years from the date of issue.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

15 TRADE AND OTHER PAYABLES

	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Trade payables	77,868	44,229
Payroll payables	45,478	45,909
Payables for purchase of property, plant and equipment	23,779	29,186
Amounts due to related parties	407	86
Rebates liabilities	9,452	6,962
Others	48,639	37,368
Total trade and other payables	205,623	163,740

All of the trade and other payables are expected to be settled within one year.

(a) Ageing analysis

As of the end of the reporting period, the ageing analysis of trade payables, based on the invoice date, is as follows:

	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Within 3 months	60,898	39,618
3 to 6 months	2,507	2,739
6 months to 1 year	6,353	98
Over 1 year	8,110	1,774
	77,868	44,229

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

16 LOANS AND BORROWINGS

	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Bank loans		
— unsecured (note i)	283,359	217,249
— secured (note ii)	255,577	10,012
	538,936	227,261

The analysis of the repayment schedule of bank loans is as follows:

	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Within 1 year or on demand	373,472	227,261
After 1 year but within 2 years	41,366	—
After 2 years but within 5 years	93,074	—
After 5 years	31,024	—
	538,936	227,261

Notes:

- (i) As at 30 June 2025, the unsecured bank loans of RMB283.3 million carried interest at annual rate of 2.25%–6.52% per annum (31 December 2024: 2.30%–2.65%) and were all repayable within one year.
- (ii) As at 30 June 2025, among the balances of secured bank loans, RMB206.8 million were pledged by the equity interest in Hangzhou Weiqiang held by the Company with interest at annual rate of 2.70% per annum and the repayment term from June 2025 to June 2032.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

17 ACQUISITION OF A SUBSIDIARY

According to the Company's announcement dated 18 December 2024, the Company entered into an acquisition intention agreement (the "**Acquisition Intention Agreement**") with Hangzhou Weiqiang and other four entities (the "**Other Target Group Companies**"), pursuant to which, the Company has conditionally agreed to acquire the controlling stake with at least 51% equity interest in Hangzhou Weiqiang by way of capital injection and acquisition of equity interest from existing shareholders of Hangzhou Weiqiang. The transactions contemplated under the Acquisition Intention Agreement is subject to the parties further entering into a formal acquisition agreement (the "**Formal Acquisition Agreement**"), pursuant to which the final consideration and form of completion shall be set forth therein.

According to the Company's announcement dated 21 May 2025, the Company, Shanghai Chenyue Weixin Medical Technology Co., Ltd.* 上海辰躍維新醫療科技有限公司 ("**Chenyue Weixin**"), Hangzhou Weiqiang, the immediate holding company of Hangzhou Weiqiang, namely Endonom Medical (Hong Kong) Co., Limited ("**Endonom Medical**") and certain intermediate holding shareholders of Hangzhou Weiqiang have entered into the Formal Acquisition Agreement, pursuant to which, the Company and Chenyue Weixin (the "**Purchasers**") conditionally agreed to acquire from Endonom Medical an aggregate of 81.83% equity interest in Hangzhou Weiqiang at a total consideration of approximately RMB512.8 million, of which the Company will acquire the controlling stake with 51.70% equity interest in Hangzhou Weiqiang at a consideration of approximately RMB324.0 million, subject to completion or waiver of the Conditions Precedents. Upon the completion of the transaction on 21 May 2025, Hangzhou Weiqiang has become a non-wholly owned subsidiary of the Company.

* English translation is for identification purpose only.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

17 ACQUISITION OF A SUBSIDIARY (Continued)

The acquisition of Hangzhou Weiqiang constituted a business combination. The following table summarises the recognised amount of the identifiable assets acquired and liabilities assumed at the date of acquisition.

	Pre-acquisition carrying amount on acquisition date RMB'000	Fair value adjustments RMB'000	Recognised amount on acquisition date RMB'000
Property, plant and equipment (Note 8 and note (i))	13,147	5,061	18,208
Intangible assets (Note 9 and note (i))	155,382	80,750	236,132
Right-of-use assets	15,398	–	15,398
Trade and other receivables	8,385	(397)	7,988
Inventories (note(i))	36,352	2,186	38,538
Cash and cash equivalents	12,770	–	12,770
Other current assets	4,261	–	4,261
Trade and other payables	(134,634)	–	(134,634)
Loans and borrowings	(122,080)	–	(122,080)
Contract liabilities	(11,058)	–	(11,058)
Lease liabilities	(17,610)	–	(17,610)
Deferred income	(470)	470	–
Deferred tax liabilities	–	(13,211)	(13,211)
Total net identifiable (liabilities)/assets	(40,157)	74,859	34,702
Goodwill			306,100
			340,802
Consideration including:			
Cash consideration			324,041
Add: Non-controlling interests			16,761
			340,802
Reconciliation of cash outflow			
Cash consideration			324,041
Less: cash of subsidiary acquired			(12,770)
Less: consideration payables			(65,493)
Net cash outflow arising from the acquisition of a subsidiary			245,778

The goodwill is attributable mainly to the skills and technical talent of Hangzhou Weiqiang's workforce and the synergies expected to be achieved from integrating Hangzhou Weiqiang into the Group's existing vascular interventional business. None of the goodwill recognised is expected to be deductible for income tax purpose.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

17 ACQUISITION OF A SUBSIDIARY (Continued)

(i) Measurement of fair values

The fair value of net identifiable assets of the acquiree is determined by the directors with reference to the valuation performed by an independent valuation firm on the acquisition date. The valuation techniques used for measuring the fair value of material assets acquired were as follows.

Intangible assets

Patents and capitalised development costs

Relief-from-royalty method: The relief-from-royalty method considers the discounted estimated royalty payments that are expected to be avoided as a result of the patents being owned.

Property, plant and equipment

Fixed assets

Replacement cost method: The replacement cost method considers the cost required to reacquire or reconstruct with the same functionality under current market conditions.

Inventories

Net realisable value method: The net realisable value method considers the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

(ii) Revenue and profit contribution

Hangzhou Weiqiang contributed revenue of RMB15.5 million and profit of RMB 3.9 million to the Group's consolidated net profit for the period from the date of acquisition to 30 June 2025.

Had the business combination taken place on 1 January 2025, the management estimated that the consolidated revenue and the consolidated net profit of the Group would have been RMB526.6 million and RMB106.9 million, respectively, for the six months ended 30 June 2025. The pro forma information is for illustrative purposes only and is not necessarily an indication of revenue and results of operations of the Group that actually would have been achieved had the acquisition been completed on 1 January 2025, nor is it intended to be a projection of future results.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

18 CAPITAL, RESERVES AND DIVIDENDS

(a) Share capital

	30 June 2025		31 December 2024	
	No. of shares		No. of shares	
	('000)	RMB'000	('000)	RMB'000
Ordinary shares, issued and fully paid:				
At the beginning of the period/year	176,000	176,000	171,000	171,000
Shares issued during the period/year (note)	–	–	5,000	5,000
At the end of the period/year	176,000	176,000	176,000	176,000
Representing:				
Domestic shares issued	71,787	71,787	71,787	71,787
H shares issued	104,213	104,213	104,213	104,213
Total ordinary shares issued at the end of the period/year	176,000	176,000	176,000	176,000

Note: The Company issued 5,000,000 shares at a price of RMB12.00 per share to the participants under restricted share scheme in 2024, of which, RMB5 million was recorded under share capital and the remaining of RMB55 million was charged to capital reserve.

(b) Purchase of own shares

During the six months ended 30 June 2025, no shares on The Stock Exchange of Hong Kong Limited were repurchased by the Company.

During the year ended 31 December 2024, the Company repurchased its own shares on The Stock Exchange of Hong Kong Limited as follows:

Month/year	Number of shares repurchased	Highest price paid per share HKD	Lowest price paid per share HKD	Aggregate price paid HKD'000	Aggregate price paid RMB'000
April 2024	800,000	26.00	26.00	20,875	18,919

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

18 CAPITAL, RESERVES AND DIVIDENDS *(Continued)*

(c) Dividends

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2025 (for the six months ended 30 June 2024: nil).

Dividends payable to equity shareholders of the Company attributable to the previous financial year, approved and paid during the interim period.

	Six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
Final dividend in respect of the previous financial year, approved and paid during the interim period, RMB nil per ordinary share (2024: RMB0.27 per ordinary share)	–	47,520

Pursuant to the shareholders' approval of the Company on 24 May 2024, a final cash dividend of RMB0.27 per share in respect of the year ended 31 December 2023 based on 176,000,000 ordinary shares totaling RMB47.5 million was declared and paid during the six months ended 30 June 2024, of which, RMB0.4 million was subsequently received by the Group since the Trust holds 1,693,000 H shares and are treated as treasury shares.

(d) Capital injection from non-controlling interests

- (i) On 25 June 2025, the Company, Chenyue Weixin, Hangzhou Weiqiang and Endonom Medical have entered into a capital injection agreement, pursuant to which, the Company and Chenyue Weixin will make a capital injection of RMB94.8 million and RMB55.2 million into Hangzhou Weiqiang, respectively. The capital injection was made in June 2025, and the Company and Chenyue Weixin held approximately 53.84% and 31.37%, respectively, equity interest in Hangzhou Weiqiang accordingly.
- (ii) Zhuhai Lingfeng Zunhe Investment Partnership Enterprise (Limited Partnership)* 珠海凌峰尊合投資合夥企業(有限合夥) ("Lingfeng investment") is the minority shareholder of Zhuhai Purui Intelligent Manufacturing Co., Ltd.* 珠海璞瑞智能製造有限公司 ("Zhuhai Purui"), which is the subsidiary of the Company. Lingfeng investment made a capital injection of RMB4.0 million into Zhuhai Purui for the six months ended 30 June 2025.

* English translation is for identification purpose only.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

19 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS

(i) Financial assets and liabilities measured at fair value

Fair value hierarchy

The following table presents the fair value of the Group's financial instruments measured at the end of the reporting period on a recurring basis, categorised into the three-level fair value hierarchy as defined in HKFRS 13, Fair value measurement. The level into which a fair value measurement is classified is determined with reference to the observability and significance of the inputs used in the valuation technique as follows:

- Level 1 valuations: Fair value measured using only Level 1 inputs i.e. unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date
- Level 2 valuations: Fair value measured using Level 2 inputs i.e. observable inputs which fail to meet Level 1, and not using significant unobservable inputs. Unobservable inputs are inputs for which market data are not available
- Level 3 valuations: Fair value measured using significant unobservable inputs

A valuation report with analysis of changes in fair value measurement is prepared by the finance team at each interim and annual reporting date, and is reviewed and approved by the head of finance department. Discussion of the valuation process and results with the head of finance department and the directors is held twice a year, to coincide with the reporting dates.

	As at 30 June 2025			
	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
<i>Recurring fair value measurement</i>				
Assets:				
— Investment in unlisted funds	—	—	260,582	260,582
— Unlisted equity investment	—	—	7,000	7,000
Total	—	—	267,582	267,582

	As at 31 December 2024			
	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
<i>Recurring fair value measurement</i>				
Assets:				
— Investment in unlisted funds	—	—	151,615	151,615
— Unlisted equity investment	—	—	7,000	7,000
— Structured bank deposits	—	—	30,000	30,000
Total	—	—	188,615	188,615

During the six months ended 30 June 2025, there were no transfers between Level 1 and Level 2, or transfers into or out of Level 3. The Group's policy is to recognise transfers between levels of fair value hierarchy as at the end of the reporting period in which they occur.

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

19 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS (Continued)

(ii) Information about Level 3 fair value measurements

	Valuation techniques	Significant unobservable inputs
Unlisted equity investment	Valuation multiples (Note i)	Changing trend of medium market multiples of comparable companies
Unlisted funds	Net asset value (Note ii)	Net asset value of underlying investments
Structured bank deposits	Discounted cash flow (Note iii)	Expected return rate

Note i: The fair value of certain unlisted equity investments is determined using valuation multiples adjusted for changing trend of medium market multiples of comparable companies. The fair value measurement is positively correlated to the changing trend of medium market multiples of comparable companies. As at 30 June 2025, it is estimated that with all other variables held constant, an increase/decrease in change of medium market multiples of comparable companies by 5% would have increased/decreased the Group's profit for the period by RMB0.4 million (31 December 2024: RMB0.4 million);

Note ii: The fair value of unlisted units in investment funds is determined referencing net asset value of underlying investments. The fair value measurement is positively correlated to net asset value of underlying investments. As at 30 June 2025, it is estimated that with all other variables held constant, an increase/decrease in net asset value of underlying investments by 5% would have increased/decreased the Group's profit for the period by RMB12.0 million or RMB11.5 million (31 December 2024: RMB6.6 million);

Note iii: The fair value of structured bank deposits is calculated by discounting the expected future cash flows. The fair value measurement is negatively correlated to expected return rate. As at 31 December 2024, it is estimated that with all other variables held constant, a decrease/increase in fair value of structured deposits by 5% would have increased/decreased the Group's profit for the year by RMB1.2 million.

The movements during the periods in the balance of these Level 3 fair value measurements was as follows:

2025	Investment in unlisted funds RMB'000	Unlisted Equity investment RMB'000	Structured deposits RMB'000	Total RMB'000
At 1 January 2025	151,615	7,000	30,000	188,615
Investment in unlisted funds	107,500	–	–	107,500
Purchase of financial assets measured at FVPL	–	–	248,000	248,000
Redemption of financial assets measured at FVPL	–	–	(278,474)	(278,474)
Net realised and unrealised gains recognised in profit or loss	1,467	–	474	1,941
At 30 June 2025	260,582	7,000	–	267,582

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

19 FAIR VALUE MEASUREMENT OF FINANCIAL INSTRUMENTS (Continued)

(ii) Information about Level 3 fair value measurements (Continued)

2024	Investment in unlisted funds RMB'000	Unlisted Equity investment RMB'000	Derivative financial liabilities RMB'000	Structured deposits RMB'000	Total RMB'000
At 1 January 2024	168,023	7,000	(491)	–	174,532
Investment in unlisted funds	2,500	–	–	–	2,500
Net unrealised gains recognised in profit or loss	7,640	–	491	–	8,131
At 30 June 2024 and 1 July 2024	178,163	7,000	–	–	185,163
Investment in unlisted funds	5,000	–	–	–	5,000
Purchase of financial assets measured at FVPL	–	–	–	30,000	30,000
Dividend received from financial assets measured at FVPL	(15,389)	–	–	–	(15,389)
Net unrealised losses recognised in profit or loss	(16,159)	–	–	–	(16,159)
At 31 December 2024	151,615	7,000	–	30,000	188,615

(iii) Fair values of financial assets and liabilities carried at other than fair value

All financial instruments carried at amortised cost were not materially different from their fair values as at 31 December 2024 and 30 June 2025.

20 COMMITMENTS

Capital commitments outstanding at 30 June 2025 and 31 December 2024 and not provided for in the financial statements were as follows:

	At 30 June 2025 RMB'000	At 31 December 2024 RMB'000
Contracted for	57,486	89,046
Authorised but not contracted for	13,060	202,151
Total	70,546	291,197

NOTES TO THE UNAUDITED INTERIM FINANCIAL STATEMENTS

(Expressed in Renminbi Yuan unless otherwise indicated)

21 MATERIAL RELATED PARTY TRANSACTIONS

- (i) During the six months ended 30 June 2025 and 2024, the Group had below transactions with Shanghai Kindly Enterprise Development Group Co., Ltd. and its subsidiaries/associates excluding the Group (together referred to as “KDL Group”):

	Six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
Sales of goods to KDL Group	5,296	9,560
Purchase of materials from KDL Group	764	672

- (ii) As at 27 March 2025, the Company, along with Song Yuan, Wang Ruiqin and Lin Sen established Shanghai INT Investment Management Co., Ltd.* 上海瑛泰投資管理有限公司 (“INT Investment Management”). The Company holds 70% equity interest in INT Investment Management. Song Yuan and Wang Ruiqin are non-executive directors of the Company, which is a related party of the Company, holding 10% equity interest in INT Investment Management separately. Lin Sen is an executive director of the Company, which is also a related party of the Company, holding holding 10% equity interest in INT Investment Management.

22 NON-ADJUSTING EVENTS AFTER THE REPORTING PERIOD

On 6 August 2025, the Company conditionally entered into a partnership agreement with Ningbo Huaige Health Investment Management Partnership Enterprise (Limited Partnership)* (寧波懷格健康投資管理合夥企業(有限合夥)), (as the general partner and the fund manager) and other limited partners (as the limited partners) in relation to the establishment of, and investment in Ningbo Huaige Guangtai Equity Investment Partnership Enterprise (Limited Partnership)* 寧波懷格廣泰股權投資合夥企業(有限合夥) (the “Huaige Guangtai Fund”).

The total capital commitment of the Huaige Guangtai Fund shall be RMB350.0 million which among the first capital commitment is RMB121.0 million. The Company shall participate in the Huaige Guangtai Fund as one of the limited partners and will make a total capital commitment of not exceeding RMB110.0 million, among which the initial capital contribution is RMB50.0 million. The Huaige Guangtai Fund will be registered in the PRC as a limited partnership with the primary objective of achieving investment returns through equity investments in companies in the fields of medical devices. Detailed information is disclosed in the Company’s announcement dated 6 August 2025.

* English translation is for identification purpose only.

DEFINITIONS

"2023 Share Incentive Scheme"	the 2023 employee share incentive scheme of the Company approved by the Shareholders on 19 December 2023
"Audit Committee"	the audit committee of the Board
"Board"	the board of Directors
"CG Code"	the Corporate Governance Code contained in Appendix C1 to the Listing Rules
"Company"	Shanghai INT Medical Instruments Co., Ltd.* (上海瑛泰醫療器械股份有限公司), a joint stock company incorporated in the PRC with limited liability, the H Shares of which are listed on the Stock Exchange (Stock code: 1501)
"CSDC"	China Securities Depository and Clearing Corporation Limited
"CSRC"	China Securities Regulatory Commission (中國證券監督管理委員會)
"Director(s)"	the director(s) of the Company
"Domestic Share(s)"	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in RMB and are unlisted Shares which are currently not listed or traded on any stock exchange
"Group" or "we" or "our"	the Company and its subsidiaries
"H Share Award and Trust Scheme" or "H Share Scheme"	the H Share Award and Trust Scheme approved by the Shareholders on 16 May 2022
"H Share Scheme Rules"	the rules governing the operation of the H Share Scheme as well as the implementation procedure
"H Shares"	share(s) in the ordinary share capital of the Company, with a nominal value of RMB1.00 each, listed on the Main Board of the Stock Exchange
"HK\$" or "Hong Kong dollars"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange, as amended, supplemented or otherwise modified from time to time
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules
"NMPA"	the National Medical Products Administration of China

DEFINITIONS

"PMMPA"	Provincial and Municipal Medical Products Administration
"PRC" or "China"	the People's Republic of China, for the purpose of this interim report, excluding Hong Kong, Macau Special Administrative Region of the PRC and Taiwan
"Prospectus"	the prospectus of the Company dated 28 October 2019 in relation to global offering of H Shares of the Company
"Reporting Period"	the six-month period ended 30 June 2025
"Remuneration Committee"	the remuneration committee of the Board
"RMB"	the lawful currency of the PRC
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
"Share(s)"	share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, including the Domestic Share(s) and the H Share(s)
"Shareholder(s)"	the shareholders of the Company
"Share Incentive Platforms"	Jingning Int Chuangyuan Partnership (Limited Partnership)* (景寧瑛泰創源合夥企業(有限合夥)) and Jingning Int Chuangqi Partnership (Limited Partnership)* (景寧瑛泰創啟合夥企業(有限合夥)), or such names as approved by the relevant PRC registration authority, limited partnerships to be established in the PRC whose general partner is Dr. Liang Dongke
"Share Incentive Scheme"	the share incentive scheme approved by the Shareholders on 17 December 2020 and the amendments to the Share Incentive Scheme approved by the Shareholders on 17 May 2021 and 18 May 2023, respectively
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary(ies)"	has the meaning ascribed thereto in the Companies Ordinance (Chapter 622 of the laws of Hong Kong)
"Substantial Shareholder(s)"	has the meaning ascribed thereto in the Listing Rules
"Supervisor(s)"	the supervisor(s) of the Company
"Supervisory Committee"	the supervisory committee of the Company
"treasury shares"	has the meaning ascribed thereto in the Listing Rules